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Alterations of Metabolic and Mitochondrial Function in Response to Weight Loss 
 
Jennie L. Zambito 
 
Obesity causes a multitude of metabolic issues in the horse, yet stepwise alterations in 
glucose and lipid metabolism, mitochondrial capacity and oxidant status during weight 
loss have yet to be analyzed. Skeletal muscle contains subsarcolemmal (SSM) and 
interfibrillar (IFM) mitochondria, which respond differently to physiological stimuli, 
impacting tissue and whole body oxidant status. We hypothesized that 8 light-type horses 
would display improvements in skeletal muscle mitochondrial subpopulation function 
and decreases in circulating oxidant status markers during weight loss from an obese (7 to 
8) to moderate (5) body condition score (BCS). Additionally, we hypothesized 
improvements in morphometric measurements, circulating metabolic markers, along with 
glucose tolerance and insulin sensitivity would also be seen. Change in BCS and percent 
weight loss were related to decreases in all morphometric measurements (p<0.05) except 
for abdominal circumference (p<0.10).  Measurements of body composition also 
decreased with regard to both weight loss parameters (p≤0.001). Circulating markers of 
lipid metabolism evaluated from non-fasting samples revealed no changes in non-
esterified fatty acid (NEFA) or triacylglyceride concentration, yet ex vivo lipolysis media 
was decreased in response to weight loss  (p=0.07) and BCS change (p=0.01). Insulin 
sensitivity calculated from baseline and post-weight loss intravenous glucose tolerance 
tests was improved after weight loss and corresponding BCS decline (p≤0.05) while the 
disposition index, reflecting β–cell responsiveness, also increased due to weight loss 
(p=0.09). Plasma nitrate decreased in response to BCS reduction (p=0.06) and percent 
 ii 
weight loss (p=0.06), whereas erythrocyte total glutathione (p=0.06) concentration 
increased with decreasing BCS, signifying improvements in oxidant status.  
Mitochondrial electron transport chain complex I and IV displayed greater activity in 
SSM than IFM (p≤0.05), while I, III, and IV in SSM had decreased activity due to BCS 
change and percent weight loss (p≤0.01). Interactions between SSM and IFM complex IV 
activity and both weight loss markers (p<0.05) were displayed. Citrate synthase activity, 
indicating mitochondrial number, was greater in SSM than IFM (p<0.0001) but remained 
unchanged with weight loss parameters. Lipid peroxidation was decreased due to BCS 
change (p=0.01) and weight loss (p=0.02), with greater concentration in SSM, but a 
larger decrease in IFM (p≤0.05). Alterations in complex activities and lipid peroxidation 
suggest IFM are more affected by weight loss, with large contributions from complex IV 
byproducts. Mitochondrial component flexibility may contribute individually to 
development and disease propagation along with athletic performance of the equine 
athlete. Lack of changes in circulating markers along with minimal changes in minimal 
model parameters suggest that while horses were obese, metabolic function was 
conserved. Further evaluation of metabolically healthy but obese horses may provide 
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Chapter I: Literature Review 
Introduction 
Obesity and its associated maladies plague both humans and horses in the United States 
today. Recent studies suggest nearly half the nation’s horses may be overweight or obese, 
with ‘easy-keeper’ breeds at particularly high risk for unwanted weight gain (Geor et al., 
2007; Henneke et al., 1983). A serious concern for horse owners and veterinarians, 
obesity is associated with equine metabolic syndrome and related conditions of insulin 
resistance, oxidative damage, chronic systemic inflammation, and laminitis (Geor et al., 
2007). While knowledge of the effects of obesity on physiological pathways and 
metabolic parameters is growing, numerous areas still remain vague. Obesity is known to 
impact insulin sensitivity with confounding effects on glucose homeostasis, lipid 
metabolism, mitochondrial function and concomitant oxidative damage. Often, weight 
loss, as a result of caloric restriction and/or exercise, is touted to be the most beneficial 
means to decrease these effects of obesity; however, little is known about the impacts of 
obesity and the metabolic alterations occurring within an individual during stepwise 
decreases in body mass.  
 
Obesity and the equine industry  
 Obesity affects a large population of the horses within the United States today. The 
prevalence of overweight and obese horses is much higher than initially estimated, with 
41% of horses in the study found to be over conditioned or obese (Pleasant et al., 2008). 
By definition, obesity arises when energy intake exceeds energy expenditure, and this 
excess energy is primarily stored within the body as triglycerides or triacylglycerols 
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(Bray, 2004). Genetics greatly influence predispositions for this phenotypic trait as 
displayed by breed differences, but other management practices such as diet and physical 
activity, along with developmental stage and age also modulate this condition 
(Kopelman, 2000). For the feral equine, the ability to store energy can be a vital means 
for survival when food sources are scarce, yet for the domestic horse where dietary intake 
is often not a concern, extended periods of obesity or cyclical fluctuations in weight gain 
and loss may cause numerous metabolic maladies.  
 
Although some horses may possess an overweight body condition for an extended period 
of time, others may gain and lose weight through the course of the year, in conjunction 
with increased or decreased work load (e.g. show season vs. winter), or seasonal 
alterations in diet such as the availability of lush pasture. Pasture can often meet or 
exceed the nutritional needs of many types of horses, despite seasonal variation between 
growing and dormant stages, along with diurnal alterations in nutrient status of grasses 
and legumes (NRC, 2007). Since starch content is contained within the chloroplast, starch 
saturation is easily achieved in warm season grasses due to chloroplast limitations, yet 
fructans are typically stored within vegetative structures, and can therefore be present in 
much higher concentrations as seen in cool season grasses (Bender and Smith, 1973; 
Ojima and Isawa, 1968).  
 
Understanding and managing forage and concentrate intake for horses of any breed, 
nutritional status, or workload, is necessary to maintain adequate health as obesity and 
over-nutrition due to improper management poses numerous health risks. Managing the 
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obese horse can be challenging for many horse owners due to the multitude of problems 
that can arise regarding metabolic function. Weight loss is often the primary solution for 
the overweight horse; however, while much is known about the effects of obesity, little 
knowledge is available regarding the effects of weight loss after a bout of obesity. While 
the average horse owner is not concerned with the specifics of why obesity is harmful to 
the horse, knowledge of how obesity and subsequent weight loss affects metabolic 
parameters can educate those marketing nutraceuticals and pharmacological agents to the 
general public. In the obese horse, insulin insensitivity, hyperglycemia, and impaired 
lipid metabolism can give rise to dysfunction within the mitochondria and increased 
oxidative damage (Geor et al., 2007). In addition, further understanding of how the horse 
handles metabolic substrates on a cellular level can provide insight into fueling the entire 
body during times of excessive nutrients and caloric restriction, which can be important 
when managing both performance, and companion equines alike. Although a reduction in 
body condition to a moderate level is beneficial for the health of an animal or person, the 
malfunctions caused by obesity within glucose processing, lipid metabolism and 
mitochondrial function may have lasting effects. In order to gain a full appreciation for 
the implications of obesity on physiological function, a thorough understanding of the 







Normal metabolic function: nutrient intake and utilization in fed vs. fasting states 
Glucose metabolism  
Hormonal regulation is central to maintaining blood glucose concentrations at a relatively 
constant level. Balance between insulin, glucagon and other hormones is necessary to 
maintain metabolic homeostasis. Normal equine blood glucose ranges 40-70 mg/dL 
(Hoffman et al., 2003); inability to maintain this narrow range results in a multitude of 
detrimental changes to overall homeostasis within the body. For example, in horses 
prolonged elevation of glucose concentrations has a toxic effect on cells (Yki-Jarven, 
1992),
 
whereas low concentrations can produce seizures and disorientation (Valberg and 
Firshman, 2009). The effects of these hormones reach far beyond their role in glucose 
metabolism and many intermediates within these pathways feed into other catabolic and 
anabolic states. Prolonged periods of fed or fasting metabolism can cause obesity and 
insulin resistance, or starvation, respectively. Achievement of optimal body condition, 
performance and physiologic mechanisms is possible with proper management and 
understanding of the detailed hormone functions within these systems. 
 
Circulating glucose can face multiple fates, including entry into the adipose tissue, 
skeletal muscle and liver. Glucose movement into the liver occurs through passive 
diffusion, where as uptake into adipose and skeletal muscle tissue is insulin dependent. 
Upon elevation of blood glucose concentration, glucose is transported into the pancreatic 
β-cell via facilitated diffusion though GLUT 2, an insulin independent transporter. 
Elevated blood glucose concentration is directly reflected in within the pancreatic β-cell 
and thus will elicit an appropriately large insulin response (Straub and Sharp, 2002). 
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Membrane depolarization occurs in response to glucose entry, leading to intracellular 
calcium release, which initiates a signaling cascade for the release of insulin-containing 
secretory vesicles via exocytosis (Straub and Sharp, 2002). 
 
Insulin is then able to reach 
skeletal muscle and adipose tissue via circulation and elicit glucose uptake to reduce 
blood glucose concentrations. 
 
When insulin reaches the target tissue, binding of the hormone to the cell-surface insulin 
receptor induces autophosphorylation at a number of tyrosine residues on the receptor. 
Phosphorylation of specific residues allow for recognition by insulin receptor substrates 
(IRS), which are recruited to the receptor at the time of insulin binding and serve as 
docking sites. The insulin receptor then phosphorylates IRS at multiple tyrosine residues, 
allowing for recognition by the p85 regulatory subunit of phosphatidyl-inositol 3-kinase 
(PI3-kinase).  Upon this activation, the p110 catalytic subunit of PI 3-kinase can then 
phosphorylate and convert phosphatidylinositol-2-phopshate (PIP2) to 
phosphatidylinositol-3-phosphate (PIP3) (Watson and Pessin, 2001). Protein kinase B is 
then activated by PIP3, which functions to recruit GLUT 4 containing vesicles to the 
plasma membrane. Facilitated diffusion of glucose into the cell can then occur, aiding in 
the decrease of blood glucose concentration. Translocation of GLUT 4 to the plasma 
membrane is primarily driven by insulin, and is thus considered an insulin dependent 
transporter (Goodyear and Kahn, 1998). Receptor sensitivity and effectiveness of the 
aforementioned signaling pathway is necessary to facilitate this response; any impairment 
can result in hyperglycemia and propagation of other associated maladies. 
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Lipid metabolism  
Fatty acid (FA) metabolism is closely intertwined with glucose metabolism within the 
skeletal muscle and adipocyte and therefore must be considered when evaluating the 
effects of obesity on metabolic parameters. Fatty acid metabolism within the body 
involves a delicate balance between multiple steps including lipolysis and long chain 
fatty acid release from adipocytes, delivery of dietary or released fatty acids to muscle 
cells via transport across the plasma membrane, lipolysis of intramuscular triglyceride 
stores, activation of the fatty acid and transport into the mitochondria for oxidation 
(Holloway et al., 2009). In order to gain a big picture understanding of how fatty acid 
release from the adipose tissue and utilization of the substrate within the muscle is 
interrelated with obesity and weight loss consideration must be given to both adipose and 
muscle tissues, including individual mitochondrial subpopulations within the muscle. 
Further, to fully understand changes associated with excess lipid stores in the body, 
familiarity with lipid metabolism in the tissues and their contribution to energy 
production and intracellular signaling is necessary.  
 
A typical ration of dietary forage and concentrate components would yield a variety of 
triacylglycerols, phospholipids and cholesterols, each contributing individually to the 
lipid profile of the horse’s diet. De novo fatty acid synthesis occurs during times of 
energy excess, in the cytosol of liver and adipose tissue cells. In this biosynthetic 
pathway, condensation reactions are coupled with the hydrolysis of ATP causing the 
reaction to be driven to completion; ultimately leading to excess storage of fats in the 
adipose tissue.  
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In a fasted or other catabolic state such as exercise, chylomicron levels decline, and the 
adipose tissue becomes the major source of fatty acids for the body (Muoio and Newgard, 
2006). A lower insulin-to-glucagon ratio, along with increased catecholamine levels due 
to a fasting/catabolic state, cause activation of hormone sensitive lipase (HSL). During 
lipolysis in the adipose tissue, HSL acts on diacylglycerols to release free fatty acids and 
glycerol into the circulation for use by other tissues. Concurrently, signaling within the 
body decreases glucose utilization while increasing fatty acid oxidation. Cytosolic citrate 
is used for synthesis of acetyl-CoA and malonyl-CoA, yet when acetyl-CoA carboxylase 
is phosphorylated and thus inactivated in the presence of AMP kinase, conversion of 
acetyl-CoA to malonyl-CoA ceases and concentrations decline. Low levels of malonyl-
CoA combined with the effects of decreased citrate concentrations result in suppression 
of de novo lipogenesis and simulation of fatty acid oxidation through removal of 
malonyl-CoA inhibition of carnitine palmitoyltransferase-1 (CPT-1) activity. Elevated 
CPT-1 activity can ultimately lead to increased flux through fatty acid β-oxidation, as 
displayed in figure 1.  Lastly, during times of increased fatty acid oxidation accumulation 
of acetyl-CoA, NADH and ATP allosterically inhibit pyruvate dehydrogenase. Overall, 
the actions of the mechanisms described during the fasting/catabolic state function to 
increase the rate of fat oxidation while decreasing glucose oxidation.  
 
Mitochondrial metabolism 
Mitochondria are double-membrane organelles specialized to convert energy dense 
macronutrients into ATP through oxidative phosphorylation, and also play a role in 
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various cellular signaling pathways including apoptosis, and cellular proliferation 
(Martinez, 2006). The production of ATP is achieved through oxidation of acetyl-CoA 
from two major sources: from the end products of glycolysis, which enter the 
mitochondrion as pyruvate and are converted to acetyl-CoA via pyruvate dehydrogenase, 
and fatty acid oxidation end products. The citric acid cycle then utilizes acetyl-CoA to 
form citrate from oxaloacetate by the action of citrate synthase, and is rate limited by the 
action of isocitrate dehydrogenase converting isocitrate into α-ketoglutarate.   For each 
acetyl-CoA to enter the cycle, three NADH
+
, a FADH2 and an ATP are generated. The 
NADH
+
 and FADH2 are then able to carry electrons, or reducing equivalents, to the 
electron transport chain, where incremental releases of energy are applied to pump 
protons across the inner mitochondrial membrane. This is accomplished through the 
action of four major enzymes embedded within the inner mitochondrial membrane; 
NADH dehydrogenase (Complex I), succinate dehydrogenase (Complex II), cytochrome 
bc1 complex (Complex III) and cytochrome c oxidase (Complex IV, figure 2).   
 
Alterations in mitochondrial number are often needed to manage ever-changing energy 
substrate loads and metabolic demands placed on various tissues. Skeletal muscle 
mitochondrial biogenesis can be stimulated through the actions of peroxisome 
proliferator-activated receptor gamma (PPAR) coactivator1-alpha (PGC-1α) (Scarpulla, 
2008). In its active form, PGC-1α interacts with nuclear receptor PPARs to increase gene 
transcription, along with the potential for PPARs to act in a feed forward fashion and 
increase PGC-1α further (Muoio and Newgard, 2006). It is through this interaction with 
PPAR that PGC-1α is able to increase mitochondrial biogenesis via increased 
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transcription of nuclear respiratory factors (NRFs), along with influencing oxidative 
phosphorylation gene regulation (Lin et al., 2002). Mitochondrial autophagy, or 
mitophagy, can also occur in response to cellular environmental factors or stressors. 
Utilization of this pathway can be activated in response to overwhelming oxidative 
damage, mitochondrial dysfunction or damage to critical proteins used for mitochondrial 
function (Lemasters, 2005). Mitochondrial number, whether in response to biogenesis or 
autophagy, can be indicative of overall aptitude of the tissue to respond to physiological 
stimuli along with providing a detailed image of disease states and energy production.  
 
While mitochondria are needed in all cell types to provide ATP, skeletal muscle contains 
two sets of biochemically and spatially distinct mitochondria: subsarcolemmal 
mitochondria (SSM), which reside beneath the plasma membrane, and interfibrillar 
mitochondria (IFM) which are located between the myofibrils (Palmer et al., 1977).  
While they function to achieve the same general goal, differences have been found in 
their morphology, biochemical properties and response to physiological stimuli, 
including exercise and stress (Cogswell et al., 1993; Manneschi and Federico, 1995; 
Palmer et al., 1985).  Subsarcolemmal mitochondria are located just beneath the 
sarcolemma and are larger, with a more lamellar shape, while IFM tend to be smaller, 
more compact and located between the contractile filaments (Koves et al., 2005).  In 
response to exercise, SSM tend to display greater increases in volume, state III 
respiration and enzymatic activity than IFM (Bizeau et al., 1998; Kreiger, 1980), and 
during times of muscle disuse SSM show more pronounced decrements (Bizeau et al., 
1998). Further, oxidative phosphorylation properties with respect to mitochondrial 
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subpopulation are different based on fiber type, and are individually affected in response 
to energy stress (Kim et al., 2002; Koves et al., 2005).  Understanding the relationship 
between SSM and IFM and their contributions to skeletal muscle metabolism can be 
instrumental in understanding the alterations caused by increases or decreases in body 
condition, and therefore will be the focus of latter portions of this review.  
 
Obesity-Related Changes in the Horse 
Thermoregulation 
While over-conditioned animals are suspected to be at higher risk for metabolic 
dysfunction, excess body fat may be advantageous to horses in cold climates. Body fat 
provides insulating properties along with providing an available energy source during 
times of low ambient temperatures. Previous studies have determined horses with a BCS 
of 7-9 require less supplemental feed during cold weather than horses with lower BCS 
(Cymbaluk and Christison, 1990). Conversely, this same property most likely induces 
heat stress in obese horses during hot/humid weather (Cymbaluk and Christison, 1990; 
Webb et al., 1989). Horses with a BCS of 7.5 or greater had a more difficult time 
dissipating heat in an ambient temperature of 31.5° C (humidity 43.8%) than horses with 
an average BCS of 5.2 (Webb et al., 1989). Further, these obese horses had a higher 
respiration rate following a light intensity exercise bout consisting of 30 min of mixed 
walk, trot and canter work. While thermoregulation is crucial to homeostatic maintenance 
of the horse, performance from both an athletic and reproductive standpoint is of great 




Currently within the equine industry, the impact of obesity on exercise performance has 
not been studied in depth. Preliminary research in this area showed a negative 
relationship between body weight and body fat percentage in performance measures of 
equine athletes (Thornton et al., 1987).  In a study evaluating body composition of 
standardbred horses competing in one-mile races, larger amounts of body fat determined 
by rump fat ultrasound were negatively correlated to running performance, indicated by 
race times (Kearns et al., 2006b). Additionally, horses completing a 151km endurance 
race were found to have lower BCS and carried less body fat (26kg) than non finishers 
(45kg) (Lawrence et al., 1992). 
 
 Despite this valuable information, the previously mentioned studies were completed on 
horses with an average BCS of 4.5 and body fat percentage of 8.65% (Kearns et al., 
2006b; Lawrence et al., 1992; Webb et al., 1989). It remains likely that horses with 
higher BCS would display further performance impairments compared to lean 
counterparts, especially if not enrolled in an exercise program.  
 
Reproductive Performance 
Body condition score to either an excessively high or low condition appears to impact 
estrous cycle length in broodmares, yet ovulation and fertility remain relatively 
unaffected with obesity. In mares with a BCS ranging from 7.5-8.5 continued to cycle 
during winter months, forgoing seasonal anestrus typically displayed by moderate and 
lean horses (Gentry et al., 2002). Higher circulating levels of leptin have been found in 
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obese mares (8.27 ± 1.02 ng/mL) compared to lean mares (~2 ng/mL), potentially 
contributing to the absence of an anestrous period in this cohort (McManus and 
Fitzgerald, 2003). This concept is further supported as when leptin levels declined, obese 
mares entered into an anestrous period. Cause of the decline during this study remains 
unknown, as it was not accompanied by a reduction of body fat percentage, but may have 
been affected by fluctuations in overall satiety (McManus and Fitzgerald, 2003).  
Conversely, other studies suggest excessive body fat in mares (BCS > 7) may prolong 
luteal phase length and interovulatory intervals when compared to thin mares (BCS 4) 
(Sessions et al., 2004). Elevated levels of leptin and insulin observed in the fatter mares, 
combined with the presence of insulin resistance were though to have caused the 
observed extensions (Sessions et al., 2004). Insulin resistance combined with other 
physiological indicators may be the influential factor between mares retaining normal 
reproductive cyclicity and the onset of dysfunction.  
 
 Guidelines for mares in gestation and lactation suggest a proper BCS before, during and 
after pregnancy should allow mares to be sufficiently fat so as to prevent loss in condition 
due to fetal development, but not so overweight as to induce metabolic stress (Quinn et 
al., 2006). Mares fed to either gain weight or maintain a BCS of 6.6-7.1 during gestation 
and lactation periods had higher successful pregnancy rates, decreased number of estrous 
cycles per conception compared to mares allowed to lose weight, with a BCS ranging 
from 6.1-3.7 (Henneke et al., 1984). Further, low levels of body fat (BCS <5) resulted in 
reduced pregnancy rates when compared to mares of increasing body condition (5-8), as 
mares with a higher BCS displayed decreased times to first estrous and first ovulation, 
 13 
indicating improved reproductive efficiency (Henneke et al., 1984). Effects of obesity on 
reproductive capability in the stallion have not been fully evaluated. Obese stallions may 
have reduced sexual performance, potentially due more to the effects of obesity on 
athleticism and thermoregulatory properties over the impact of obesity on sperm 
production (Quinn et al., 2006). Influences of obesity on both mare and gelding metabolic 
function is often of a more pressing concern, as if the horse is able to remain in a healthy 
homeostatic state, then reproductive function will also be conserved.  
 
Metabolic Impacts of Obesity 
Obesity is known to cause alterations in transport and metabolism of various energy 
substrates, yet exact mechanisms for obesity-associated disturbances remain elusive. 
Obesity-induced insulin resistance can be linked to many pathologic distrubances within 
the skeletal muscle, ultimately resulting in disruptions in oxidative and storage pathways 
for glucose and lipid molecules. Insulin resistance by definition is a condition of low 
insulin sensitivity in which the ability of insulin to lower circulating glucose levels is 
impaired (Henry, 2003). Originally, insulin resistance was thought to arise from extended 
periods of hyperglycemia, and subsequent insulin release from the pancreatic beta cells. 
Elevated levels of both glucose and insulin over time cause receptor insensitivity to 
normal levels and as the cycle propagates the condition worsens. It is now known that 
multiple factors affect insulin resistance, including this pathway and others arising from 




Adipose tissue metabolism 
Partitioning of lipids between adipose tissue and other peripheral tissues is integral in 
coordinating energy balance and signaling pathways regarding substrate utilization. As 
adipose tissue is designed to store triacylglycerides, enhanced lipolysis and free fatty acid 
flux from adipocytes exposes skeletal muscle and other tissues to a substantial fatty acid 
load, resulting in lipid accumulation in these tissues (Horowitz and Klein, 2000). 
Mircoarray experiments on obese leptin-deficient mice indicate genes encoding for 
transcription factors involved in lipogenesis, including sterol regulatory-element binding 
protein-1c (SREBP-1c) and PPAR-γ, are down-regulated in adipose tissue, yet are up-
regulated in the liver (Nadler et al., 2000; Soukas et al., 2000). While PPAR-γ is not 
typically expressed at high levels in the liver (Nadler et al., 2000; Soukas et al., 2000), 
induction of transcription is caused by elevated circulating levels of triacylglycerides, 
suggesting relative expression is indicative of fuel repartitioning during times of obesity 
(Attie and Scherer, 2009). Moreover, adipose tissue expansion needed to accommodate 
excess nutrients places demands on vascularization and remodeling pathways. If these 
pathways lag behind the need for increased triacylglyceride storage, hypoxic conditions 
may emerge, leading to increased inflammation via macrophage recruitment (Attie and 
Scherer, 2009). Mitochondrial dysfunction, such as enzyme impairment or electron 
transport chain deficiency, in the adipocyte during times of hyperglycemia can also 
contribute to impairment of energy balance, as a decrease in respiratory capacity can 
reduce GLUT 4 translocation along with increasing reactive oxygen species production, 
further propagating local and systemic inflammation. (Lin et al., 2005; Shi et al., 2008). 
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Skeletal muscle glucose and lipid metabolism 
The interplay of lipid metabolism with other energy substrates and signaling pathways is 
disconcerted in animals consuming diets in extreme excess of their current needs, or of 
those in an obese body condition. It has been well documented that obesity causes 
impaired insulin signaling and glucose tolerance (Hoffman et al., 2003; Kronfeld, 2005), 
manifested by decreased insulin-stimulated glucose transport and metabolism in skeletal 
muscle and adipocytes (Reaven, 1995) and increased levels of circulating free fatty acids 
(Kahn and Flier, 2000). In combination with decreased GLUT4 levels or translocation 
(Kahn and Flier, 2000) seen with an obese phenotype, dysfunction in the insulin signaling 
pathway is further propagated.  
 
With the onset of obesity, triacylglycerides are not only stored in the adipose tissue, but 
begin to accumulate at unhealthy levels in the skeletal muscle, liver, kidney and heart 
(Muoio and Newgard, 2006) due to increases in circulating triacylglycerides and free 
fatty acids. Increased levels of fatty acid binding protein on the plasma membrane or fatty 
acid translocase/CD36 on the plasma membrane but not the outer mitochondrial 
membrane (Bonen et al., 2004) may play a critical role in increased fatty acid uptake, 
accumulation of intramuscular lipids and impaired insulin signaling (Consitt et al., 2009). 
Increases in intramuscular triglyceride stores, which, in addition to impairing GLUT4 
translocation, may also propagate the development of insulin resistance (Montell et al., 
2001).  Further, long chain fatty acyl-CoAs are shunted away from CPT-1 and are instead 
are preferentially partitioned toward synthesis of signaling intermediates such as 
diacylglycerols and ceramide.  Accumulation of these molecules combined with the 
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effects of excess intramuscular lipid stores are thought to activate serine-kinases (Holland 
et al., 2007; Yu et al., 2002), along with impacting protein kinase c and other downstream 
insulin signaling molecules (Schmitz-Peiffer, 2002), thereby preventing proper 
translocation of GLUT4 in an insulin-dependent manner. Without the necessary actions 
of this transporter, the insulin mechanism fails to reduce circulating glucose 
concentrations and, therefore, contributes to obesity-induced insulin resistance.  
 
An imbalance between fatty acid uptake and fatty acid oxidation in obese individuals is 
often seen, contributing to the aforementioned impairment in glucose tolerance along 
with decrements in regulatory steps of fatty acid oxidation. Reduced activity of carnitine 
palmitoyltransferase-1 (CPT-1), β-hydroxy acyl-CoA dehydrogenase, citrate synthase 
and cytochrome c oxidase have been reported in samples of skeletal muscle from obese 
subjects (Simoneau et al., 1999), along with overall decreased mitochondrial content 
(Kim et al., 2000). Overexpression of CPT-1 in L6 cells caused an increase in fatty acid 
oxidation and protected cells against fatty acid induced insulin resistance (Muoio and 
Newgard, 2006), suggesting that increasing β-oxidation could help to correct maladies 
driven by this accumulation. Obese individuals have been reported to have an increased 
ratio of glycolytic to oxidative enzyme capacity, as determined by hexokinase to citrate 
synthase activity levels, yet not as elevated as the ratios seen in type 2 diabetic subjects 
(Simoneau and Kelley, 1997). Further, this ratio was negatively correlated with insulin 
sensitivity, providing increasing evidence that an alteration in metabolic preference may 
contribute to insulin resistance seen in an obese individual.  
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Mitochondrial function and oxidative status  
While mitochondrial oxidative phosphorylation is a highly efficient process, a small 
amount of electrons can prematurely bind with oxygen to form free radicals. Further, 
under certain conditions such as obesity, excessive production of reactive oxygen species 
has been found and attributed to the mechanisms implicated in insulin resistance and 
metabolic syndrome (Martinez, 2006).  A low degree pro-inflammatory state has also 
been associated with obesity, causing impairments in the oxidative stress and antioxidant 
mechanisms leading to activation of nuclear factor kappa-β in the presence of excessive 
reactive oxygen species (Martinez, 2006).  Additionally, reactive oxygen species have 
been attributed to propagating insulin resistance and paracrine communication between 
adipocytes and macrophages, thereby mediating inflammatory changes by means of free 
fatty acids and tumor necrosis factor-α (Valerio et al., 2006).   
 
Accumulation of intramuscular lipid may place additional strain on the mitochondria and 
create a larger disconnect between metabolic pathway fluidity. For example, a metabolic 
profiling study demonstrated that obesity-induced rates of β-oxidation overwhelmed the 
citric acid cycle, resulting in incomplete fatty acid degradation (Koves et al., 2008). Lack 
of cycle completion caused accumulation of mitochondrial-derived by-products, 
including acylcarnitines, which potentially can contribute to obesity induced insulin 
resistance. Moreover, electron transport chain activity in the vastus lateralis muscle, 
assessed from complex activities normalized to creatine kinase activity, in type II diabetic 
and obese human subjects was found to be diminished when compared to that of healthy 
lean counterparts, even when corrected for total mitochondrial content (Ritov et al., 
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2005). Although the exact mechanism linking mitochondrial capacity and insulin 
resistance propagation is unknown, these findings suggest a link between insufficient 
coupling and/or reduced enzymatic activity in insulin resistant obese individuals. 
 
As previously mentioned, skeletal muscle contains different populations of mitochondria 
which respond differently to physiological stimuli.  In response to hyperglycemia and 
hyperlipidemia situations changes in individual size, population size, proteins involved in 
substrate utilization, electron transport chain (ETC) function, and reactive species 
production have been observed in rodents (Dabkowski et al., 2010; Dabkowski et al., 
2008a). Typically, in an obese or type II diabetic model, the SSM tends to be more 
affected, while in a type I diabetic model, the IFM display greater dysfunction 
(Dabkowski et al., 2010; Williamson et al., 2009).  The hyperglycemic environment 
caused in response to obesity and metabolic syndrome leads to enhanced reactive oxygen 
species (ROS) production, which can facilitate enhanced apoptosis along with causing 
oxidative damage to the cell and its contents (Williamson et al., 2009). Further, reduced 
activity of citrate synthase and CPT-1 in obese skeletal muscle has been used to infer 
reduced mitochondrial number (Kim et al., 2000), a concept confirmed by lower 
mitochondrial DNA in obese human individuals compared to lean counterparts (Ritov et 
al., 2005). 
 
Despite contributions from other sources, the mitochondrion is regarded as the primary 
site of production of ROS (Kelley et al., 2002b). Several locations within the ETC are 
prone to formation of ROS, and due to the inclusion of iron-sulphur centers, which can 
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react with other ROS to produce the hydroxyl radical, can cause mitochondrial 
dysfunction (Fridovich, 1995). Dysfunctional mitochondria can result in further insult to 
the inner mitochondrial membrane, producing oxidative damage to lipids and proteins, 
which in turn limits adequate production of ATP. The effects of functional changes in 
mitochondria extend to fatty acid metabolism as well. In age-matched lean (BMI 23.3 ± 
0.7) and obese (BMI 37.6 ± 2.2) humans, citrate synthase, a common marker of total 
muscle mitochondrial volume and capacity for fatty acid oxidation was decreased in 
obese individuals (Holloway et al., 2007).  Due to the role of the mitochondria within 
metabolism and generation of ROS and implications of cellular apoptosis with 
corresponding dysfunction, subpopulations of mitochondria may be differentially 
affected by physiological parameters presented with obesity and subsequent weight loss. 
Inability for mitochondrial function to return to a normal functioning state could be 
detrimental for the animal, as prolonged periods of increased oxidative damage could 
lead to further disease and impairment in the future.  
 
Differences in body condition  
Effects of obese vs. lean body condition on metabolic function 
As the skeletal muscle has the ability to transition easily between oxidative and glycolytic 
metabolism, this tissue adapts to a given set of metabolic cues, thus having the largest 
differences between obese and lean phenotypes.  This malleable characteristic may allow 
skeletal muscle mitochondria to rebound after prolonged periods in an obese state. In a 
16-week lifestyle modification program, obese non-diabetic volunteers were placed on a 
calorie-reduced diet and a moderate-intensity exercise program (Menkishova et al., 
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2006). Significant improvements were noted with regard to insulin sensitivity, whole 
body fat oxidation and electron transport chain oxidative capacity. Despite this increase, 
mitochondrial number, as measured by citrate synthase activity and mitochondrial DNA, 
quantification was not altered.  
 
It has been well documented that weight loss improves insulin sensitivity; however, little 
is known about the impact of weight loss on skeletal muscle mitochondria, potentially 
due to the recent development in knowledge on the effects of obesity on mitochondrial 
functions (Toledo and Goodpaster, 2013). Current research in this area appears to be 
confounding with respect to improving mitochondrial capacity. In a 1 yr weight loss 
study of obese women who lost an average of 55 kg, fatty acid oxidation was unchanged, 
along with mRNA content of CPT 1 and PGC-1α indicating mitochondrial biogenesis is 
not active during periods of weight loss (Berggren et al., 2008). Yet, in a study of obese 
women who had undergone moderate weight loss by caloric restriction and light exercise, 
succinate dehydrogenase activity was increased (Kern et al., 1999).  Therefore, it is 
currently unclear if changes in mitochondrial function associated with weight loss are due 
primarily to alterations in metabolic function, or are manifested as a side effect of 
contractile activity during exercise.   
 
Evaluation of markers of metabolism and oxidative damage through a weight loss period 
can provide a stepwise analysis of changes seen from an overall body perspective to a 
cellular level of function. Knowledge to be gained from this study has implications 
spanning multiple facets, as information on cellular changes are important to determine 
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how substrates are being handled on a chemical level, while implications of cellular 
products on body function is needed to elucidate the changes seen with regard to an 
increase and decrease in body condition.  Within the equine industry, substrate utilization 
is needed for optimal performance along with maintenance, meaning the impact of data to 
be gained from this study has the ability to reach the performance industry and small 
farm practices alike. By developing a baseline understanding of the changes associated 
with weight loss on metabolic function, we can further evaluate the role of nutraceutical 
and pharmaceutical interventions designed to improve or adjust these parameters.  
 
As of now, the majority of studies completed evaluating these parameters have been 
conducted either using two groups of animals: a lean and an obese group, or evaluating 
snapshot samples of pre- and post-weight loss. While this information is important in 
elucidating the damaging effects of obesity, little is known about how these parameters 





Figure 1: Entry of fatty acids into the mitochondria 
ACS: Acyl-CoA synthetase, CPT-1: carnitine palmitoyltransferase-1, CPT-2: carnitine 





Figure 2: Electron Transport Chain Adapted from (Brownlee, 2001) 
Q: Ubiquinol, e-: electron, Cyt c: cytochrome c, ΔμH+:  change in proton gradient   
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CHAPTER II: JOURNAL ARTICLE I 
WEIGHT LOSS INFLUENCE ON NUTRITIONAL STATUS AND METABOLIC 
MARKERS IN A MATURE EQUINE MODEL  
 
Abstract 
Obesity is known to impact insulin sensitivity with confounding effects on glucose 
homeostasis, lipid metabolism, mitochondrial function and concomitant oxidative 
damage. Often, weight loss as a result of caloric restriction and/or exercise is touted as 
beneficial in decreasing these adverse effects of obesity; however, little is known 
regarding lasting effects of obesity on metabolic parameters after weight loss has 
occurred. We hypothesized that 8 light-type horses would display improvements in 
morphometric measurements, circulating metabolic markers, along with glucose 
tolerance and insulin sensitivity during weight loss from an obese (7 to 8) to moderate (5) 
body condition score (BCS). Effects of change in BCS or percent weight loss were 
evaluated using the mixed procedure of SAS with repeated measures. Change in BCS and 
percent weight loss were related to decreases in all morphometric measurements (p<0.05) 
except for abdominal circumference (p<0.10).  Measurements of body composition also 
decreased with regard to both weight loss parameters (p≤0.001). Circulating markers of 
lipid metabolism revealed no changes in non-esterified fatty acid (NEFA) or 
triacylglyceride concentration, yet ex-vivo lipolysis media was decreased in response to 
weight loss  (p=0.07) and BCS change (p=0.01). Insulin sensitivity calculated from 
baseline and post-weight loss intravenous glucose tolerance tests was improved after 
weight loss and corresponding BCS decline (p≤0.05) while the disposition index, 
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reflecting β–cell responsiveness, also increased due to weight loss (p=0.09). Lack of 
changes in circulating markers along with minimal changes in minimal model parameters 
suggest that while horses were obese, metabolic function was conserved. Further 
evaluation of metabolically healthy but obese horses may provide insight as to 
management and treatment of obesity associated maladies.  
 
Key Words 
Horse, weight loss, glucose, insulin, obesity 
 
Introduction 
Obesity among horses within the United States has reached an all time high, with nearly 
half of the nation’s horses being considered either overweight or obese (Geor et al., 2007; 
Henneke et al., 1983). Obesity causes a multitude of metabolic issues in the horse, 
including impairment of glucose tolerance and insulin signaling, which compounded with 
compromised lipid metabolism and mitochondrial function can cause increased cellular 
damage and propagation of disease states.  It has been well documented that obesity in 
the horse can cause impaired insulin signaling and glucose tolerance (Hoffman et al., 
2003; Kronfeld, 2005), manifested by decreased insulin-stimulated glucose transport and 
metabolism in skeletal muscle and adipocytes (Kahn and Flier, 2000) and increased 
levels of circulating free fatty acids (Kahn and Flier, 2000). In combination with 
decreased GLUT4 transporter levels or translocation (Kahn and Flier, 2000) seen with an 
obese phenotype, dysfunction in the insulin signaling pathway is further propagated. As 
of now, the majority of studies completed evaluating these parameters have been 
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conducted using two groups of animals: a lean and an obese group. While the effects of 
obesity on physiologic pathways have been studied, many areas still remain vague, 
particularly with regard to the lasting effects of obesity on metabolic function and 
stepwise alterations in metabolic capacity during weight loss. Often, weight loss, as a 
result of caloric restriction and/or exercise, is suggested to be the most beneficial method 
to decrease these effects of obesity; however, little is known about potential lasting 
effects of obesity on metabolic parameters after weight loss has occurred. Therefore; the 
objective of this study was to characterize the effects of weight loss on whole body 
markers of glucose and lipid metabolism and insulin sensitivity. Additionally, we sought 
to determine the effects of weight loss on cellular markers and regulators of glucose and 
lipid metabolism, including both β-oxidation and lipid biosynthesis. We hypothesized 
that weight loss would improve markers of insulin sensitivity and glucose tolerance, 
while decreasing levels of circulating triglycerides and increasing levels of non-esterified 
fatty acids. Further, we suspected lipolysis within the adipose tissue and β-oxidation of 
the lipids in skeletal muscle would increase.  
 
Materials and Methods 
The Middle Tennessee State University Institutional Animal Care and Use Committee 1 
approved all methods and procedures used in this experiment. Horses were body 2 
condition scored by two trained individual reviewers and horses assigned a body 3 
condition score (BCS) of 7 or greater were admitted to the study. In addition, horses 4 
selected for this screening process were known to not have any predisposing metabolic 5 
conditions including Cushing’s Disease or Metabolic Syndrome as defined for horses. 6 
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Eight, healthy, mature (5-19 yrs) light type mixed sex (n=6 mares, n=2 geldings) horses 7 
of either Quarter Horse, Standardbred or Tennessee Walking Horse breeds from the 8 
Middle Tennessee State University Horse Center herd were admitted based on these 9 
parameters for use in this study (table 1).  10 
 11 
Sampling Periods and Diet 12 
Prior to and during the study, all horses received the same type of mixed grass hay and 13 
commercial concentrate (Purina Strategy, Land O’Lakes Purina Mills, St. Louis, MO), 14 
with ad libitum access to water. Dietary analysis was measured on concentrate samples 15 
from 10 different bags and hay grab samples from at least 25 bales over 5 random dates 16 
during the study (Equi-analyticial, Ithaca, NY, table 2 and 3). Further, study horses were 17 
group housed in pastures with run-in shelters when not individually stalled over the entire 18 
study. Pastures did contain some plant life; however, there was not enough coverage to 19 
make a significant contribution to the diet and therefore was not included in digestable 20 
energy (DE) intake calculations or dietary analysis. Due to limiting labor factors, 21 
individual feed offerings and refusals were not measured daily, but estimated based on 22 
average flake weight and concentrate cup weight, taken from 10 total measurements.   23 
 24 
The baseline sampling period (BSP) began on d0 and continued until d14, during which 25 
time horses were maintained on their current dietary intake, with a mean DE intake of 26 
21.1 Mcal/d. Upon entry into the weight loss period (WLP, d15), horses received a 30% 27 
DE reduction by altering amount of concentrate and hay offered. Horses remained on this 28 
level of restriction until d43, at which time calculations were made for maintenance DE 29 
 28 
requirements based on current body weight, as described by the equation (NRC, 2007) 30 
DE (Mcal/d) = 1.4 + (0.03 x BW) to achieve steady weight loss . In order to facilitate 31 
further weight loss, a 30% reduction from the maintenance requirement was calculated 32 
and implemented throughout the remainder of the study (mean DE intake 14.01). At no 33 
point during the study did horses consume less than 1.5% BW in forage per day to ensure 34 
proper hindgut health.   35 
 36 
During both the BSP and the WLP, all horses were subjected to exercise not exceeding 37 
the parameters of light workload as defined by the NRC. Horses were exercised on 38 
average between 1-3 hr/wk, with an approximate gait breakdown of 40% walk, 50% trot 39 
and 10% canter. Horses not broke to ride were lunged or worked in a round pen.  40 
 41 
Sample Acquisition & Analysis 42 
Body Condition Score, Cresty Neck Score and Morphometric Measurements 43 
Two individuals assigned a body condition score (BCS) based on a 1-9 scale (Henneke et 44 
al., 1983) and a cresty neck score (CNS) on a 0-5 scale (Carter et al., 2009). Scores were 45 
assigned on a whole or half score basis and the average was used for statistical analysis. 46 
Morphometric measurements consisted of body weight, wither height, body length, neck 47 
length (NL), neck crest height, neck circumference at 0.25, 0.5, and 0.75 of NL, girth 48 
circumference, and abdominal circumference, in accordance with the measurements 49 
made by Carter and colleagues (Carter et al., 2009). Measurements, BCS and CNS were 50 
made on d 0, 14, 28, 42, 70, and 98. Body length was measured from the intermediate 51 
tubercale of the humerous (point of the shoulder) to the ischiatic tuberosity (point of the 52 
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buttock). All neck measurements were made with the neck in a relaxed position, at an 53 
approximate 45° angle. Neck length was measured from the poll to the highest point of 54 
the wither. Neck crest height was measured at 0.5 neck length, from the differentiation of 55 
musculature and tissue above the nuchal ligament (assessed by palpation and visual 56 
identification) to the dorsal midline of the neck. Neck circumferences were measured at 57 
0.25, 0.5 and 0.75 of neck length.   Girth circumference was measured immediately 58 
behind the slope of the wither, caudal to the elbow (olecranon tuber). Abdominal 59 
circumference was taken at two-thirds the distance from the intermediate tubercale of the 60 
humerous (point of the shoulder) to the point of the hip (tuber coxae). Horses were 61 
clipped in the areas where measurements were made initially to ensure later 62 
measurements were taken at the same location.  63 
 64 
Body Composition Measurements 65 
Rump fat thickness (RFT) was measured using B-mode ultrasound (Sonovet 2000, 66 
5mgHz) (Kearns et al., 2006a; Kearns et al., 2006b) on d 0, 14, 28, 42, 70, and 98. The 67 
site for measurement was determined by measuring half the distance from the point of the 68 
hip (tuber coxae) to the point of the buttock (ischiatic tuberosity); and half of the distance 69 
from this point to the spine. Scans were made on alternating sides so as not to be affected 70 
from healing biopsy sites. Body fat percentage was estimated using the following 71 
equation (Kane et al., 1987); Percent Fat = 2.47 + 5.47 (rump fat in cm). Fat mass was 72 
calculated by multiplying percent fat and total body mass. Fat free mass was determined 73 
by the difference between total body mass and fat mass.  74 
 75 
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Circulating Metabolic Biomarkers 76 
Non-fasting blood samples (~35 mL) were collected via jugular venipuncture on d 0, 14, 77 
21, 28, 35, 42, 56, 70, and 98, placed into serum and sodium heparin vacutainers 78 
(Vacutainer, Franklin Lakes, NJ).  Sodium heparin tubes were immediately placed on ice, 79 
while serum samples were allowed to clot at room temperature for at least 20 min before 80 
being centrifuged at 3000 x g for 15 min. Plasma and serum aliquots were removed and 81 
stored at -20° C until analysis. Serum non-esterified fatty acid (NEFA) and plasma 82 
triacylglyceride (TG) concentrations were measured in duplicate using a commercially 83 
available kit (HR-NEFA and L-Type TG Wako Diagnostics, Richmond, VA) as 84 
instructed by the kit insert. The coefficient of variation accepted between duplicates was 85 
5% and 10% for NEFA and TG respectively (O'Connor et al., 2007; O'Connor et al., 86 
2004).  Glucose (Autokit glucose, Wako Diagnostics, Richmond, VA) and insulin (Coat-87 
A-Count Insulin, Siemens, Los Angeles, CA) concentrations were also determined using 88 
commercially available kits, where the accepted coefficient of variation between 89 
replicates was 5% and 10%, respectively.  90 
 91 
Frequently Sampled Intravenous Glucose Tolerance Tests (FSIGT) 92 
All horses were subjected to a FSIGT on d 12 or 13 (end of BSP, FSIGT 1) and again at 93 
the end of the WLP (FSIGT 2). As all horses did not exit the study on the same day, 94 
FSGIT 2 was administered within 3 d of final morphometric measurements, biopsies, and 95 
blood sampling. Concentrate feeding was withheld for at least 12 h prior to the test but 96 
horses had access to grass hay the morning of and during the FSIGT. The protocol for 97 
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this test was determined from previously published methods, described in detail below 98 
(Hoffman et al., 2003).  99 
 100 
Horses were weighed the morning of the test using an electronic scale and catheterized 101 
(Abbocath, 14g, 5.5 in, Abbott Laboratories, Abbott Park, IL) using aseptic technique and 102 
lidocaine anesthesia between 0800 and 0930. Horses were grouped randomly to allow for 103 
test staggering if multiple horses were to be tested on the same day. A glucose bolus, 104 
given at 0.3g/kg BW (50% dextrose solution, Phoenix Pharmaceutical, Inc, St. Joseph, 105 
MO), was infused via catheter within a 2 min period. Timing for all other samples began 106 
after the infusion finished, where the 1 min sample signifies the collection of a sample 1 107 
min post glucose infusion, et cetera. Twenty min post-glucose infusion, an exogenous 30 108 
mIU/kg BW insulin bolus (Humulin R, Willow Birch Pharmaceutical, Inc, Taylor, MS) 109 
was administered through the catheter. After each dose, the catheter, extension set and 110 
stopcock were thoroughly flushed with heparinized saline.  111 
 112 
The test was conducted over ~4 h, during which blood samples (~25 mL) were collected 113 
at the following time points: -30 (baseline), 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 19, 114 
22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 80, 90, 100, 120, 150 and 180 min post glucose 115 
administration. An additional 240 min time point was sampled during FSIGT 1 to allow 116 
adequate time for blood glucose to return to baseline for a more appropriate 117 
representation of the data when completing Minimal Model analysis.  118 
 119 
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Samples were collected into sodium heparin or serum tubes (Vacutainer, Franklin Lakes, 120 
NJ). Sodium heparin tubes were placed immediately on ice while serum tubes were 121 
allowed to clot at room temperature for at least 20 min before being placed on ice. All 122 
tubes were centrifuged at 3000 x g for 15 min. Aliquots were removed and stored at -20° 123 
C until analysis. To determine insulin concentration, serum aliquots were analyzed in 124 
duplicate using a commercially available radioimmunoassay (Coat-A-Count Insulin, 125 
Siemens, Los Angeles, CA) as directed by the package insert. After the decanting step, 126 
tubes were placed in a gamma counter (Perkin Elmer, Wallac 1470 Wizard Auto Gamma-127 
counter, Waltham, MA), where each replicate was counted for 1 min. Plasma aliquots 128 
were measured in duplicate using a commercially available kit (Autokit Glucose, Wako 129 
Diagnostics, Richmond, VA) adapted to a 96 well plate (Nielsen et al., 2010). In brief, 9 130 
μL samples, standards, and controls were each loaded into the plate, followed by 300 μL 131 
of buffer solution. Plates were then incubated for 2 min, and read on a UV 132 
spectrophotometer (Spectramax Plus 384, Molecular Devices, Sunnyvale, CA). Each of 133 
these kits have been previously validated for equine samples (Hoffman et al., 2003). The 134 
accepted coefficient of variation between replicates was 5% and 10% for glucose and 135 
insulin, respectively (Nielsen et al., 2010). Area under the curve (AUC) for glucose and 136 
insulin was calculated using the trapezoidal method, with individual data points from 137 
each FSIGT (Nielsen et al., 2010). The Minimal Model Software Program (MinMod 138 
Millenium, Version 6.2) (Boston et al., 2003) was used to calculate glucose effectiveness 139 
(Sg), insulin sensitivity (Si), acute insulin response to glucose (AIRg) and disposition 140 
index (DI). Baseline glucose (GB) and insulin (IB) are calculated using initial baseline 141 
glucose and insulin values in addition to values of each curve after returning to baseline 142 
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at the end of the test. The highest concentration of glucose after intravenous injection is 143 
noted as G0. Any animal that did not fit the model with an R
2
>0.9 was removed from the 144 
model prior to statistical analysis (FSIGT 1; n=1, FSIGT 2; n=0).  145 
 146 
Neck Fat Biopsies 147 
Neck fat biopsies were collected on d 0, 14, 28, 42, 70, and 98. Prior to biopsy collection, 148 
horses had biopsy sites clipped and scrubbed with chlorhexadine solution followed by an 149 
isopropyl alcohol rinse. Horses were then sedated with xylazine (0.5mg/kg BW) and were 150 
administered lidocaine anesthesia at the neck (2.5cc) site. Alternating sides were used for 151 
consecutive biopsies so as to allow time for sites to fully heal before further sampling 152 
occurred.  153 
 154 
Neck fat biopsies were obtained at approximately 0.5 neck length (measured as described 155 
above), centered between the differentiation of musculature and tissue above the nuchal 156 
ligament using aseptic techniques (Liburt et al., 2012). A small incision, approximately 2 157 
cm, was made through the skin and connective tissue to allow access to the neck fat pad. 158 
An adequate sample was held with a hemostat and dissected out using a scalpel blade. 159 
Incisions were closed with staples, left to heal for 10 d, when staples were removed. 160 
Samples were taken on alternating sides per biopsy to allow sites to fully heal. Post-161 
collection, adipose tissue samples were weighed and allocated for an ex vivo lipolysis 162 
assay conducted immediately. 163 
 164 
Lipolysis Assay 165 
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The lipolysis assay was conducted as described previously (Ippagunta et al., 2011) with 166 
slight modifications.  A minimum of two 100 mg pieces of adipose tissue were incubated 167 
in Ringers buffer, with added BSA (fatty acid free, Sigma-Aldrich, St. Louis, MO) for 3 h 168 
at 37° C in a shaking water bath. Media sampled were collected and stored at -20° C until 169 
analysis for non-esterified fatty acids (NEFA, NEFA-HR kit, Wako, Richmond, VA) and 170 
glycerol (free glycerol reagent, Sigma-Aldrich, Inc., St. Louis, MO) via colorimetric 171 
analysis following the kit instructions. Accepted coefficient of variation between 172 
duplicates was 5% and 10% for NEFA and glycerol, respectively. Concentrations of 173 
NEFA and glycerol were adjusted for tissue weight and are expressed as mean μmol 174 
released per g of tissue.  175 
 176 
Statistical Analysis 177 
Data are expressed as mean ± SEM. Normality of all data were assessed prior to 178 
statistical analysis (SAS Institue, V9.3, Cary, NC). Any variable found to be non-179 
normally distributed by evaluation of kurtosis and skewness values, along with 180 
significance in tests for location (students t and sign tests) and normality (Shapiro-Wilk 181 
and Klomogorov-Smirinov tests) where p ≤ 0.05, were log10 transformed. The effect of 182 
BCS change and percent weight loss was tested for all data using proc MIXED procedure 183 
of SAS with repeated measures. Gender, horse, age and date were included in the class 184 
statement during the repeated measures analysis. The model with the best fit according to 185 
Akaike’s Information Criterion used a compound symmetry structure. A Pearsons 186 
Correlation was run using the proc CORR procedure of SAS, with Bonferroni correction 187 
to prevent the incidence of type I errors when performing multiple comparisons. For all 188 
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data except correlations, p<0.05 was considered significant and trends were noted at 189 
p<0.10. Due to the bonferroni correction, p<0.0032 was considered significant and trends 190 




Body, Morphometric and Composition Measurements    195 
A summary of individual horse characteristics including age, sex, breed, wither height, 196 
body length and neck length can be found in table 4. Horses on the study transitioned 197 
from a mean BCS of 7.81 ± 0.13 to a moderate body condition, 5.0 ± 0.0 during the 198 
course of the weight loss period. Change in body condition score and weight loss were 199 
related to decreases in girth circumference (p<0.04), abdominal circumference (p<0.08), 200 
cresty neck score (p<0.0001), neck crest height (p<0.0001), and all neck circumference 201 
measurements (p<0.01, table 5).  Mean body weight decreased during the weight loss 202 
period from 548.41 ± 28.74 kg to 501.36 ± 27.81 kg, corresponding to decreasing BCS 203 
during this time. Similarly, rump fat thickness, percent body fat, fat mass and fat free 204 
mass decreased in relationship to both weight loss parameters (p≤0.001) and are 205 
summarized by day in table 6.  206 
   207 
Circulating Metabolic Markers 208 
Evaluation of serum NEFA (figure 1A) and plasma TG (figure 1B) as markers of 209 
alterations in lipid metabolism revealed no differences due to change in BCS or percent 210 
weight loss. As markers of carbohydrate metabolism, glucose concentration (figure 1C) 211 
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displayed a significant increase when evaluated in relationship to change in BCS 212 
(p=0.01) but not with regard to percent weight loss. Conversely, insulin concentration 213 
(figure 1D) did not differ with change in BCS, but displayed a trend when evaluated with 214 
percent weight loss (p=0.06).  215 
 216 
Lipolysis  217 
Media collected from the lipolysis assay displayed a trending decrease in NEFA release 218 
due to weight loss (p=0.07) and BCS change (p=0.01, figure 2A). Free glycerol 219 
concentration from the same samples did not differ due to either weight loss factor 220 
(p>0.14, figure 2B).  221 
 222 
FSIGT and Minimal Model Parameters 223 
Minimal model parameters calculated from FSIGT glucose and insulin concentrations 224 
displayed variable results with regard to statistical model components (table 7). Glucose 225 
effectiveness (Sg) or AIRg were not different due to weight loss parameters. Despite this 226 
result, Si displayed an increase due to BCS change and percent weight loss (p<0.04). In 227 
contrast, DI displayed no relationship to change in BCS, yet a trend was noted with 228 
regard to percent weight loss during the study (p=0.09).  Baseline glucose (GB), as 229 
calculated from beginning and end of the FSIGT decreased, with a trend noted for BCS 230 
change (p=0.06) and a significant difference in response to weight loss percentage 231 
(p=0.002). Baseline insulin (IB) and G0, the highest concentration of glucose post-232 
intravenous injection, were not different due to either model parameter for weight loss 233 
(p>0.21).  234 
 37 
 235 
Area under the curve for glucose and insulin during the FSIGT was calculated utilizing 236 
the trapezoidal method, and analyzed in accordance with other variables. Glucose AUC 237 
(figure 3A) decreased in response to percent weight loss (p=0.0004) and change in BCS 238 
(p=0.05). A similar effect was seen for insulin AUC (figure 3B), where when analyzed 239 
with regard to BCS change, a significant difference was detected (p=0.02); however, 240 
when analyzed for effect of percent weight loss, no difference was found. 241 
 242 
Correlations  243 
Correlations between collected data were analyzed in two separate sets: (1) analyzing all 244 
morphometric measurements, body composition data, circulating metabolic markers and 245 
lipolysis media concentrations of NEFA and FG, and (2) analyzing only data collected on 246 
days 14 and 96 including all minimal model parameters in accordance with the dates 247 
FSIGT were completed. A summary of correlations described in set 1 can be found in 248 
table 7. Weight was found to be correlated to girth circumference (r=0.84), abdominal 249 
circumference (r=0.62), neck circumference at 0.25 (r=0.79), 0.5 (r=0.69), and 0.75 NL 250 
(r=0.76), and fat free mass (r=0.99), where p<0.0001 for all correlations. A trend was 251 
also noted for the correlation between fat mass and weight (r=0.42, p=0.003). As body 252 
condition score decreases, a trending correlation with decreasing lipolysis NEFA 253 
concentration (r=0.43, p=0.004) was displayed. 254 
 255 
Many of the same correlations were noted when comparing the aforementioned variables 256 
with minimal model parameters; however; due to a more stringent Bonferronis correction 257 
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as more variables were included in the correlation, only a few significant relationships 258 
were determined. Body condition score (r=0.75, p=0.001) and cresty neck score (r=0.73, 259 
p=0.001) were found to have positive correlations with AUC glucose. Area under the 260 
insulin FSIGT curve displayed positive correlations with fat mass (r=0.71, p=0.0019) and 261 
Gb (r=0.80, p=0.0002, data not shown). 262 
 263 
Discussion 264 
Body composition is an important factor to consider when evaluating metabolic function, 265 
specifically when related to glucose metabolism (Pedersen et al., 2003; Reaven, 1995). 266 
Horses included in the current study displayed decreases in all morphometric and body 267 
composition measurements during weight loss. As the Henneke body condition scoring 268 
system is subjective and can vary slightly due to each independent assessor (Henneke et 269 
al., 1983), morphometric measurements were also included to provide a more 270 
quantitative, comprehensive representation of regional adiposity differences during 271 
weight loss (Carter et al., 2009). Baseline mean cresty neck scores were similar to those 272 
found in insulin resistant ponies (Tinworth et al., 2012); yet overall BCS of the ponies 273 
was 6.0 ± 0.9, signifying a greater amount of regional adiposity than our horses which 274 
were at a greater BCS. In accordance with decreasing body condition score, all 275 
morphometric measurements including girth circumference, neck crest height, and 0.25, 276 
0.5 and 0.75 neck circumference decreased.  277 
 278 
 Rump fat thickness is a measured parameter directly reflecting fat mass in the body 279 
(Westervelt et al., 1976). The concurrent decrease in rump fat with body weight suggests 280 
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horses were loosing fat mass during the course of the study. Calculations of fat mass and 281 
fat free mass also displayed patterns reflecting this concept, whereas body weight 282 
decreased, fat mass decreased from 46.37 ± 4.39 to 29.11 ± 3.10 kg and fat free mass 283 
declined 502.04 ± 27.14 to 472.25 ± 26.54 kg. The decrease in fat free mass suggests 284 
utilization of lean body mass sources for energy homeostasis consistent with calorie 285 
restriction. The light exercise program was not rigorous enough to increase muscle mass 286 
and as horses were accustomed to this level of activity no muscular adaptation to 287 
workload was expected.  288 
 289 
Compared to other morphometric measurements, abdominal circumference displayed the 290 
smallest decrease over time, which may play a role in the lack of fluctuations seen in 291 
metabolic markers and minimal model parameters. In humans, intraabdominal fat 292 
deposits appear to have a direct role in disrupting glucose and lipid homeostasis (Leibel 293 
et al., 1989). As intraabdominal deposits drain directly into the portal vein, thereby 294 
resulting in high concentrations of hepatic free fatty acids which may interfere with 295 
hepatic catabolism of insulin along with overproduction of very low density lipoproteins 296 
(Leibel et al., 1989; Smith et al., 1985). The resultant increase in circulating insulin 297 
concentration may propagate insulin insensitivity over time. It is possible that during the 298 
process of fat deposition in the horse, abdominal fat is deposited last and also 299 
metabolized later during the weight loss process. In a study evaluating fat deposition in 300 
response to different dietary sources, the greatest amount of fat lay down occurred in the 301 
neck, with the smallest amount over the withers and loin (Suagee et al., 2008). 302 
Comparing this concept to neck crest fat, where a higher CNS is often linked to metabolic 303 
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syndrome predisposition (Carter et al., 2009; Treiber et al., 2006), it is plausible that due 304 
to the moderate CNS scores (2-3) seen during this study, the horses had not deposited 305 
enough fat to cause alterations in many of the metabolic parameters measured.  306 
 307 
Additionally, specific fat deposits have varying metabolic functions and therefore may 308 
contribute differently to energy homeostasis during weight loss (Liburt et al., 2012). 309 
Within the horse, it is possible that the role of neck fat relating to homeostatic function 310 
gives an accurate yet localized overview of adipose tissue function in this model. As the 311 
neck fat crest is easy to access for sampling purposes, many groups have analyzed the 312 
metabolic function of this fat deposit (Liburt et al., 2012). Despite its value due to ease of 313 
accessibility, analysis of other fat deposits may be instrumental to fully elucidating the 314 
contributions of each deposit and changes associated with weight loss within adipose 315 
tissue. We found a decrease in NEFA release due to both weight loss parameters but no 316 
change in free glycerol during our measurement of lipolysis. These differences may be 317 
due to the 3 to 1 ratio of fatty acids to the glycerol backbone in TG (Ippagunta et al., 318 
2011). Combined with the lack of differences in serum NEFA and plasma TG with either 319 
weight loss parameter, it is possible that while horses were overweight, the excess 320 
condition did not cause unhealthy lipid metabolism.  321 
 322 
Additionally, a potential explanation for the lack of differences in circulating NEFA and 323 
TG values is that horses were not fasted at the time of sampling. Samples obtained from 324 
non-fasting horses displayed lower levels of NEFA (O'Connor et al., 2007) due to 325 
alterations between fed and fasting state metabolism. While most of the horses on the 326 
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study were receiving mainly grass hay and a very small quantity of concentrate, the 327 
possibility remains that if horses had been sampled prior to morning feed times different 328 
results may have been displayed. This would explain the elevated glucose concentrations 329 
that would otherwise suggest horses were hyperglycemic both during baseline and post-330 
weight loss. Despite the significant difference in glucose concentration due to change in 331 
BCS and the trend noted for insulin concentration in relationship to percent weight loss, it 332 
is difficult to determine if this was a true weight loss response or a result of time of 333 
sampling post feeding. A more accurate representation of glucose and insulin 334 
concentrations due to weight loss is observed during the FSIGT, and will be discussed 335 
further.  336 
 337 
As a better representation of fasting glucose concentration, Gb calculated from beginning 338 
and end of each FSIGT glucose concentrations, displayed significant decreases due to 339 
both weight loss and BCS change. This suggests that while initial alterations to glucose 340 
metabolism may have been occurring, they had not advanced to implicating other 341 
pathways measured. Upon evaluation of minimal model parameters along with glucose 342 
and insulin curve responses it is apparent that large individual variability is observed. 343 
While Si displayed an improvement, the lack of change in Sg, or AIRg suggest that while 344 
horses were obese, carbohydrate metabolic function was not entirely compromised. 345 
Increases in Si, the capacity for insulin to promote glucose disposal (Hoffman et al., 346 
2003), can be contributed to weight loss, as in previous studies low intensity exercise 347 
alone did not produce improvements in Si (Carter et al., 2010). Interestingly, AIRg values 348 
observed during baseline when horses were obese are similar to those of moderately 349 
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obese horses (BCS 6-6.9) observed by Hoffman and colleagues (Hoffman et al., 2003).  350 
After weight loss, AIRg values were consistent with those reported in literature for horses 351 
with a BCS range of 5-5.9 (Hoffman et al., 2003). The trend observed between DI and 352 
percent weight loss may represent initial changes in endogenous insulin release, which 353 
may have been amplified if a larger sample size had been used. Previously reported 354 
literature demonstrates DI between horses of non-obese (BCS 5.0-5.9) and obese (BCS 7-355 
9) condition did not differ, suggesting adequate ability in obese animals for AIRg to 356 
compensate for limited Si (Hoffman et al., 2003); a phenomenon which also may be 357 
present as horses transition through decreasing body condition scores.   358 
 359 
Some variability between FSIGT 1 and 2, along with intraassay variation may 360 
additionally contribute to the lack of difference between FSIGT dates. In a previous study 361 
comparing multiple methods for determining insulin sensitivity and glucose tolerance, 362 
repeated tests displayed Si, Sg and AIRg mean coefficient of variation of 24%, 26% and 363 
12%, respectively (Pratt et al., 2005). While utilization of the FSIGT and minimal model 364 
analysis is still an accurate measurement of glucose and insulin dynamics, it is important 365 
to consider the role of variability when interpreting results. In order to represent 366 
individual horse differences in FSIGT responses during baseline (date 1) and after weight 367 
loss (date 2) figure 4 depicts glucose (A) and insulin (B) curves. Horse numbers 368 
correspond to those in table 1. Horse variability greatly influenced the results of this 369 
study. Although no statistical differences were noted for many of the minimal model 370 
parameters, the physiological implications of individual horse responses to the FSIGT 371 
hold value in understanding how the body responds to decreases in body fat and weight. 372 
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When evaluated as a whole, significant differences in area under the curve for both 373 
glucose and insulin concentrations suggest that horses were compromised in some aspect 374 
of carbohydrate metabolism, but not to the extent to produce statistical differences in 375 
minimal model compartment parameters.  376 
 377 
When evaluating the overall implications of this study, it remains plausible that while 378 
horses were considered obese at the start of the study, from a metabolic perspective they 379 
were not unhealthy. The term “metabolically healthy obese” has been coined in human 380 
health to describe obese individuals exhibiting relatively normal metabolic functions 381 
despite being as overweight as those presenting with metabolic dysfunction and 382 
nutritional diseases (Bonora et al., 1991; Sims, 2001; Wildman et al., 2008).  It is 383 
hypothesized that the incidence of this phenotype is relatively prevalent, with up to 30% 384 
of the adult obese population possessing reduced central adiposity, lower adipocyte stress 385 
and decreased inflammation (Denis and Obin, 2013; Kloting et al., 2010). While insulin 386 
action is preserved in these subjects despite increasing body mass index (Bluher, 2012; 387 
Bluher, 2010; Kloting et al., 2010), it is not yet understood whether these individuals are 388 
genetically predisposed to maintain insulin sensitivity or whether the phenotype is 389 
inherently unstable and can evolve rapidly to an insulin resistant state (Kim and Reaven, 390 
2008).  Despite horses included in this study beginning at an obese BCS, relatively 391 
moderate CNS scores may signify a similar phenomenon within the selected population. 392 
Horses with a greater adipose deposition may produce a different outcome, as horses may 393 
transition into an unhealthy phenotype during this time. By selecting for horses without 394 
history of laminitic issues or known insulin resistance, we may have chosen a subset of 395 
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horses with resistance to developing metabolic dysfunctions. Moreover, this may suggest 396 
that while obesity is not a desired phenotype for the horse, that animals enrolled in an 397 
exercise program may be additionally protected from the onset of insulin resistance and 398 
other obesity-related metabolic maladies.  399 
 400 
Looking forward, increasing the sample size for a study evaluating weight loss markers 401 
may be necessary to both eliminate confounding effects of horse-to-horse variability 402 
along with obtaining samples both during weight loss and weight gain. As many of the 403 
studies involving FSGIT with minimal model analysis and other metabolic studies have 404 
used between 6-10 horses, we suspected that this sample number would be adequate to 405 
elucidate changes due to weight loss as well (Hoffman et al., 2003; Liburt et al., 2012; 406 
Pratt et al., 2005; Tinworth et al., 2012). Also, collected data from this study could be 407 
utilized for a power analysis to determine sample number for future work in this area.  408 
 409 
In conclusion, horses may exhibit a metabolically preserved obesity phenotype that is 410 
relatively protected from alterations in glucose and lipid metabolism. Deposition of fat 411 
more equally throughout the body as opposed to large deposits in the neck crest or 412 
intraabdominal regions may contribute to this phenomenon. Additionally modifications to 413 
insulin sensitivity and thus glucose and insulin concentrations in response to weight loss 414 
during an FSIGT may signify beginning metabolic changes that if horses were allowed to 415 
deposit more adipose tissue may cause further impairment over time. Future studies are 416 
needed to examine effects of the length of time in an obese state as well as stepwise 417 
 45 
changes in weight gain in order to fully elucidate mechanisms behind obesity induced 418 
metabolic dysfunction.  419 
 420 
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Tables and Figures 430 
Table 1: Summary of individual characteristics of horses enrolled in study 431 


















1 10 M Quarter Horse 142 158 71 
2 6 M Tennessee Walker 148 137 71 
3 13 M Standardbred 160 156 101 
4 19 G Quarter Horse 149 150 86 
5 5 M Quarter Horse 147 152 81 
6 10 G Quarter Horse 170 165 97 
7 19 M Quarter Horse 151 159 95 
8 15 M Quarter Horse 157 165 104 
   
Mean ± SEM 153 ± 3 155 ± 3 88 ± 4 
 432 
1 
For sex categorization M represents mare and G represents gelding.  433 
2
 Measured from the ground to the highest point of the wither 434 
3 Measured from the point of the shoulder to the point of the rump 435 
4 Measured from the poll to the point of union between neck musculature and the wither  436 
 437 
  438 
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Table 2: Nutrient analysis of grass hay and concentrate, as fed 439 
Nutrient, as fed Grass Hay Concentrate 
Dry Matter (%) 95.8 93.4 
Digestable Energy (DE,  Mcal/kg) 1.85 2.84 
Crude Protein (g/kg) 51.5 150.1 
Acid Detergent Fiber (ADF, g/kg) 371.8 166 
Neutral Detergent Fiber (NDF, g/kg) 625.8 330.8 
Water Soluble Carbohydrates (WSC, g/kg) 56.0 89.4 
Ethanol Soluble Carbohydrates (ESC, g/kg) 15.5 51.7 
Starch (g/kg) 14.3 131.4 
Non-fiber Carbohydrates (NFC, g/kg) 156.8 350.9 
Crude Fat (g/kg) 28.6 59.3 
Calcium (g/kg) 6.03 12.91 
Phosphorus (g/kg) 0.83 8.15 
Sodium (g/kg) 0.218 2.369 
 440 
Table 3: Percent composition of diet on a dry matter basis 441 
Nutrient, % dry matter Grass Hay Concentrate 
Crude Protein, % 5.4 16.1 
Acid Detergent Fiber, % 38.8 17.8 
Neutral Detergent Fiber, % 65.4 35.4 
Water Soluble Carbohydrates, % 5.9 9.6 
Ethanol Soluble Carbohydrates, % 1.6 5.5 
Starch, % 1.5 14.1 
Non-fiber Carbohydrates, % 16.4 37.6 
Crude Fat, % 3 6.3 
Calcium, % 0.63 1.38 
Phosphorus, % 0.09 0.87 
Sodium, % 0.023 0.254 
 442 
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Table 4: Morphometric measurements during weight loss  444 
 

















Mean 7.81 7.75 7.44 7.38 6.13 5.00 . . 






Mean 194 195 194 193 193 189 0.04 0.01 






Mean 215 212 208 206 202 199 0.08 0.06 






Mean 2.69 2.63 2.64 2.56 2.19 2.07 <0.0001 <0.0001 






Mean 12 12 10 9 9 7 <0.0001 <0.0001 
SEM 1 1 1 1 1 1 
  




Mean 79 80 78 77 77 74 0.002 0.01 
SEM 2 1 2 2 1 2 
  




Mean 101 99 94 94 96 91 0.003 0.002 
SEM 3 3 2 2 3 1 
  




Mean 118 117 112 110 114 108 0.003 <0.0001 
SEM 3 3 3 3 4 3     
 445 
1 
Assessment based on a 1-9 scale (Henneke et al., 1983) 446 
2 
All measurements made in cm 447 
3
 Measured immediately behind slope of wither, caudal to elbow 448 
4
 Measured at two thirds distance from point of shoulder to point of hip 449 
5
 Assessment based on 1-5 scale (Carter et al., 2009) 450 
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6
 Measured at 0.5 neck length (measured from poll to highest point of the wither), from 451 
the differentiation of musculature and tissue above the nuchal ligament (discerned from 452 
visual and palpation assessment) 453 
7
 Neck circumferences taken at 0.25, 0.5 and 0.75 neck length (measured from poll to 454 
highest point of the wither) 455 
  456 
 50 
Table 5: Association of body fat measurements with BCS change and percent weight loss 457 
 458 











0 14 28 42 70 98 
  
Weight (kg) 
Mean 548.4 546.2 534.2 530.1 509.8 501.4 . . 







Mean 11.1 11.3 10.4 9.5 7.1 6.1 <0.0001 <0.0001 





Mean 8.52 8.62 8.15 7.87 6.33 5.83 <0.0001 <0.0001 






Mean 46.7 46.9 42.7 40.9 32.0 29.1 <0.0001 <0.0001 
SEM 4.4 4.3 1.9 2.6 2.7 3.1 
  




Mean 502.0 499.3 491.5 489.1 477.8 472.3 0.002 <0.0001 
SEM 27.1 26.8 26.9 26.9 22.5 26.5     
 459 
1
 Measured by B-mode ultrasound, site determined by measuring half the distance from 460 
the point of the hip (tuber coxae) to the point of the buttock (ischiatic tuberosity); and 461 
half of the distance from this point to the spine, units expressed in cm 462 
2
 Percent fat = 2.47 + (5.47 x rump fat thickness in cm) 463 
3
 Fat mass = percent fat x body weight 464 
4
 Fat free mass = body weight – fat mass 465 
 466 
  467 
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Figure 1 A-D: Effects of decreasing body condition and percent weight loss on 468 
circulating metabolic indicators. Horses (n = 8) were enrolled in a baseline-sampling 469 
period lasting from d0 to d14, followed by a caloric restriction from d15 to d98, where 470 
from d15 to d43 horses received a 30% digestible energy reduction, and from d44 to d 98 471 
horses received a 30% restriction from maintenance digestible energy. Non-fasting blood 472 
samples were taken on d 0, 14, 21, 28, 35, 42, 56, 70, and 98 and were analyzed for 473 
serum non-esterified fatty acids (NEFA) and insulin, along with plasma triacylglycerides 474 
(TG) and glucose concentrations. The main effect of change in body condition score 475 
(BCS) and percent weight loss were analyzed for each variable, with data points 476 
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Figure 2 A-B: Influence of weight loss on lipolysis markers. Horses (n = 8) were 499 
enrolled in a baseline-sampling period lasting from d0 to d14, followed by a caloric 500 
restriction from d15 to d98, where from d15 to d43 horses received a 30% digestible 501 
energy reduction, and from d44 to d 98 horses received a 30% restriction from 502 
maintenance digestible energy. On d 0, 14, 28, 42, 70, and 98, a neck fat biopsy was 503 
collected and immediately allocated for an ex vivo lipolysis assay. Media collected from 504 
the assay was analyzed for non-esterified fatty acids (NEFA) and free glycerol 505 
concentrations. The main effect of change in body condition score (BCS) and percent 506 
weight loss were analyzed for each variable, with data points representing values at 507 
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Figure 2 A-B: Influence of weight loss on lipolysis markers. Horses (n = 8) were 513 
enrolled in a baseline-sampling period lasting from d0 to d14, followed by a caloric 514 
restriction from d15 to d98, where from d15 to d43 horses received a 30% digestible 515 
energy reduction, and from d44 to d 98 horses received a 30% restriction from 516 
maintenance digestible energy. On d 0, 14, 28, 42, 70, and 98, a neck fat biopsy was 517 
collected and immediately allocated for an ex vivo lipolysis assay. Media collected from 518 
the assay was analyzed for non-esterified fatty acids (NEFA) and free glycerol 519 
concentrations. The main effect of change in body condition score (BCS) and percent 520 
weight loss were analyzed for each variable, with data points representing values at 521 
corresponding points of BCS change or weight loss, respectively. 522 
 523 
  524 
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Figure 3 A-B: Glucose and insulin curves during baseline and end weight loss FSIGT. 525 
Horses (n = 8) were enrolled in a baseline-sampling period lasting from d0 to d14, 526 
followed by a caloric restriction from d15 to d98, where from d15 to d43 horses received 527 
a 30% digestible energy reduction, and from d44 to d 98 horses received a 30% 528 
restriction from maintenance digestible energy. On d 12-13 for the baseline sampling 529 
period and d 94-95 for the weight loss period a frequently sampled intravenous tolerance 530 
test (FSIGT) was administered to each horse in accordance with published methods 531 
(Hoffman et al., 2003). A glucose bolus (0.3 g/kg BW, 50% dextrose solution) was given 532 
at time point 0, followed by an exogenous insulin bolus (30 mIU/ kg BW, Humulin R) 533 
administered at minute 20, indicated by the green arrows. Blood samples were taken at -534 
30, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 19, 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 535 
80, 90, 100, 120, 150 and 180 min post glucose administration and were analyzed for 536 
plasma glucose and serum insulin. Area under the curve was calculated using the 537 
trapezoidal method. The main effect of change in body condition score (BCS) and 538 
percent weight loss were analyzed for each variable, with data points representing values 539 
at corresponding points of BCS change or weight loss, respectively. 540 
 541 
  542 
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Figure 3 A-B: Glucose and insulin curves during baseline and end weight loss FSIGT. 543 
Horses (n = 8) were enrolled in a baseline-sampling period lasting from d0 to d14, 544 
followed by a caloric restriction from d15 to d98, where from d15 to d43 horses received 545 
a 30% digestible energy reduction, and from d44 to d 98 horses received a 30% 546 
restriction from maintenance digestible energy. On d 12-13 for the baseline sampling 547 
period and d 94-95 for the weight loss period a frequently sampled intravenous tolerance 548 
test (FSIGT) was administered to each horse in accordance with published methods 549 
(Hoffman et al., 2003). A glucose bolus (0.3 g/kg BW, 50% dextrose solution) was given 550 
at time point 0, followed by an exogenous insulin bolus (30 mIU/ kg BW, Humulin R) 551 
administered at minute 20, indicated by the green arrows. Blood samples were taken at -552 
30, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 19, 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 553 
80, 90, 100, 120, 150 and 180 min post glucose administration and were analyzed for 554 
plasma glucose and serum insulin. Area under the curve was calculated using the 555 
trapezoidal method. The main effect of change in body condition score (BCS) and 556 
percent weight loss were analyzed for each variable, with data points representing values 557 
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Figure 4 A-B: Representative illustrations of glucose (A) and insulin (B) curves during 565 
FSIGT by horse and date. Horses (n = 8) were enrolled in a baseline-sampling period 566 
lasting from d0 to d14, followed by a caloric restriction from d15 to d98, where from d15 567 
to d43 horses received a 30% digestible energy reduction, and from d44 to d 98 horses 568 
received a 30% restriction from maintenance digestible energy. On d 12-13 for the 569 
baseline sampling period (Date 1) and d 94-95 for the weight loss period (Date 2) a 570 
frequently sampled intravenous tolerance test (FSIGT) was administered to each horse in 571 
accordance with published methods (Hoffman et al., 2003). A glucose bolus (0.3 g/kg 572 
BW, 50% dextrose solution) was given at time point 0, followed by an exogenous insulin 573 
bolus (30 mIU/ kg BW, Humulin R) administered at minute 20. Blood samples were 574 
taken at -30, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 19, 22, 23, 24, 25, 27, 30, 35, 40, 50, 575 
60, 70, 80, 90, 100, 120, 150 and 180 min post glucose administration and were analyzed 576 
for plasma glucose and serum insulin. Horses are numbered 1 through 8, corresponding 577 
with the assignments described in table 1, in order to illustrate independent horse 578 
variability during the study. 579 
 580 
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Figure 4 A-B: Representative illustrations of glucose (A) and insulin (B) curves during 583 
FSIGT by horse and date. Horses (n = 8) were enrolled in a baseline-sampling period 584 
lasting from d0 to d14, followed by a caloric restriction from d15 to d98, where from d15 585 
to d43 horses received a 30% digestible energy reduction, and from d44 to d 98 horses 586 
received a 30% restriction from maintenance digestible energy. On d 12-13 for the 587 
baseline sampling period (Date 1) and d 94-95 for the weight loss period (Date 2) a 588 
frequently sampled intravenous tolerance test (FSIGT) was administered to each horse in 589 
accordance with published methods (Hoffman et al., 2003). A glucose bolus (0.3 g/kg 590 
BW, 50% dextrose solution) was given at time point 0, followed by an exogenous insulin 591 
bolus (30 mIU/ kg BW, Humulin R) administered at minute 20. Blood samples were 592 
taken at -30, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 19, 22, 23, 24, 25, 27, 30, 35, 40, 50, 593 
60, 70, 80, 90, 100, 120, 150 and 180 min post glucose administration and were analyzed 594 
for plasma glucose and serum insulin. Horses are numbered 1 through 8, corresponding 595 
with the assignments described in table 1, in order to illustrate independent horse 596 
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Table 6: Minimal model parameters during baseline sampling and at the end of weight 602 





















GB (mg/dL) 159.9 ± 28.7 113.8 ± 4.5 0.07 0.003 
IB (mU/mL) 4.51 ± 0.80 4.81 ± 0.43 0.53 0.96 
G0 (mg/dL) 290 ± 18 329 ± 20 0.21 0.99 
Sg (min-1) 0.0077 ± 0.0023 0.0234 ± 0.0110 0.41 0.81 
Si (x10-4 L*mU-1*min-1) 1.078 ± 0.270 4.319 ± 1.592 0.04 0.01 
AIRg (mU*min*L-1) 278.9 ± 57.6 217.0 ± 61.2 0.15 0.14 




 Calculated from FSIGT  607 
  Sg refers to glucose sensitivity  608 
  Si refers to insulin sensitivity 609 
  AIRg refers to acute insulin response to glucose 610 
  DI refers to the disposition index 611 
  GB refers to calculated baseline glucose concentration 612 
  IB refers to calculated baseline insulin concentration 613 
  G0 refers to highest concentration of glucose after bolus intravenous injection 614 
2
 Sampled on d12 or d13 615 
3
 Sampled on d 95 or d 96 616 
4
 Mean ± SEM
  617 
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Table 7: Correlations between morphometric measurements, body composition, 618 






P values reflect significance and trends identified with bonferroni corrections, where 622 
significance (*) determined at p≤0.0032 and trends (#) noted when p≤0.0047.  623 
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CHAPTER III: JOURNAL ARTICLE II 624 
CHANGES IN OXIDANT STATUS AND MITOCHONDRIAL FUNCTION IN 625 
RESPONSE TO WEIGHT LOSS IN AN OBESE HORSE MODEL  626 
Abstract 627 
Obesity causes a multitude of metabolic issues in the horse, yet stepwise alterations in 628 
mitochondrial capacity and oxidant status during weight loss have yet to be analyzed. 629 
Skeletal muscle contains subsarcolemmal (SSM) and interfibrillar (IFM) mitochondria, 630 
which respond differently to physiological stimuli, impacting tissue and whole body 631 
oxidant status. We hypothesized that 8 light-type horses would display improvements in 632 
skeletal muscle mitochondrial subpopulation function and decreases in circulating 633 
oxidant status markers during weight loss from an obese (7 to 8) to moderate (5) body 634 
condition score (BCS). Effects of change in BCS or percent weight loss were evaluated 635 
using the mixed procedure of SAS with repeated measures. Plasma nitrate decreased in 636 
response to BCS reduction (p=0.06) and percent weight loss (p=0.06), whereas 637 
erythrocyte reduced glutathione (p=0.06) concentration increased with decreasing BCS.  638 
Mitochondrial electron transport chain complex I and IV displayed greater activity in 639 
SSM than IFM (p≤0.05), while I, III, and IV in SSM had decreased activity due to BCS 640 
change and percent weight loss (p≤0.05). Interactions between SSM and IFM complex IV 641 
activity and both weight loss markers (p<0.05) were displayed. Citrate synthase activity, 642 
indicating mitochondrial number, was greater in SSM than IFM (p<0.0001) but remained 643 
unchanged with weight loss parameters. Lipid peroxidation was decreased due to BCS 644 
change (p=0.01) and weight loss (p=0.02), with greater concentration in SSM, but a 645 
larger decrease in IFM (p≤0.05). Alteration in complex activities and lipid peroxidation 646 
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suggest IFM are more affected by weight loss, with large contributions from complex IV 647 
byproducts. Mitochondrial component flexibility may contribute individually to 648 
development and disease propagation along with athletic performance of the equine 649 
athlete.  650 
 651 
Key Words 652 
Mitochondria, horse, weight loss, oxidant status, metabolism 653 
 654 
Introduction 655 
Within the United States, obesity among horses has reached an all time high, where 656 
nearly half of the nations horses are considered overweight or obese (Pleasant et al., 657 
2008). Obesity-related metabolic changes are well known within the horse, including 658 
impairment of glucose tolerance and insulin signaling, which compounded with 659 
compromised lipid metabolism and mitochondrial function can cause increases in 660 
oxidative damage (Geor et al., 2007; Pleasant et al., 2008).  While the effects of obesity 661 
on physiologic pathways have been studied, many areas still remain vague, especially 662 
with regard to the lasting effects of obesity on metabolic function and stepwise alterations 663 
in metabolic capacity during weight loss. Within the muscle, mitochondrial 664 
subpopulations may be differentially affected, but any impairment in function may give 665 
rise to increased reactive oxygen species through leaky electron transport chain 666 
complexes (Dabkowski et al., 2010). Elevated levels of oxidative damage can further 667 
propagate the aforementioned dysfunction associated with obesity (Muoio and Newgard, 668 
2006).  Due to these and other effects, weight loss is often the desired goal, ideally 669 
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translating a reduction in body condition into reversal of the impaired functions. 670 
However, most studies in which effects of obesity have been evaluated utilized two 671 
comparison groups; a lean or moderate and obese body condition models as opposed to 672 
evaluating the effects of weight loss within a specific individual. Therefore, this study 673 
was conducted to quantify the degree of oxidative damage and anti-oxidant defense along 674 
with identifying functional differences in mitochondrial subpopulations of skeletal 675 
muscle relative to body condition change and weight loss. We hypothesized that weight 676 
loss would decrease circulating levels of nitric oxide, while increasing glutathione and 677 
glutathione peroxidase levels. At the tissue level, lipid peroxidation would decrease 678 
corresponding to a decrease in body condition. Further, we suspected that 679 
subsarcolemmal mitochondria would show an increase in function, while interfibrillar 680 
mitochondria would remain relatively unchanged. 681 
 682 
Materials and Methods 683 
The Middle Tennessee State University Institutional Animal Care and Use Committee 684 
approved all methods and procedures used in this experiment. Horses were body 685 
condition scored by two individual, experienced reviewers and horses with assigned an 686 
body condition score (BCS) of 7 or greater (Henneke et al., 1983), were admitted to the 687 
study. In addition, horses chosen for this screening process were known to not have any 688 
predisposing metabolic conditions including Cushing’s Disease or Metabolic Syndrome. 689 
Eight, healthy, mature (5-19 yrs) light type mixed sex (n=6 mares, n=2 geldings) horses 690 
of Quarter Horse, Tennessee Walking Horse, or Standardbred breeds from the Middle 691 
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Tennessee State University Horse Center herd were admitted for use in this study (Table 692 
1).  693 
 694 
Sampling Periods and Diet 695 
Prior to and during the study, all horses received the same type of mixed grass hay and 696 
commercial concentrate (Purina Strategy, Land O’Lakes Purina Mills, St. Louis, MO), 697 
with ad libitum access to water. Dietary analysis was measured on concentrate samples 698 
from 10 different bags and hay grab samples from at least 25 bales over 5 random dates 699 
during the study (Equi-analyticial, Ithaca, NY, table 2 and 3). Further, study horses were 700 
group housed in pastures with run-in shelters when not individually stalled over the entire 701 
study. Pastures did contain some plant life; however, there was not enough coverage to 702 
make a significant contribution to the diet and therefore was not included in DE 703 
calculations or dietary analysis. Due to limiting labor factors, individual feed offerings 704 
and refusals were not measured daily, but estimated based on average flake weight and 705 
concentrate cup weight, taken from 10 total measurements.   706 
 707 
The baseline sampling period (BSP) began on d0 and continued until d14, during which 708 
time horses were maintained on their current dietary intake, with a mean DE intake of 709 
21.1 Mcal/d. Upon entry into the weight loss period (WLP, d15), horses received a 30% 710 
DE reduction by altering amount of concentrate and hay offered. Horses remained on this  711 
level of restriction until d43, at which time calculations were made for maintenance DE 712 
requirements based on current body weight, as described by the equation (NRC, 2007) 713 
DE (Mcal/d) = 1.4 + (0.03 x BW). In order to facilitate further weight loss, a 30% 714 
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reduction from the maintenance requirement was calculated and implemented throughout 715 
the remainder of the study (mean DE intake 14.01). At no point during the study did 716 
horses consume less than 1.5% BW in forage per day to ensure proper hindgut health.   717 
 718 
During both the BSP and WLP, all horses were subjected to exercise not exceeding the 719 
parameters of light workload as defined by the NRC. Horses were exercised on average 720 
between 1-3 hr/wk, with an approximate gait breakdown of 40% walk, 50% trot and 10% 721 
canter. Horses not broke to ride were lunged or worked in a round pen. 722 
 723 
Sample Acquisition and Analysis 724 
Morphometric Measurements and Body Condition Score 725 
Two experienced individuals assigned a body condition score (BCS) based on a 1-9 scale 726 
(Henneke et al., 1983). Scores were assigned on a whole or half score basis and the 727 
average was used for statistical analysis. Morphometric measurements consisted of body 728 
weight, wither height, body length, girth circumference, and abdominal circumference, in 729 
accordance with the measurements made by Carter and colleagues (Carter et al., 2009). 730 
Measurements and BCS were made on d 0, 14, 28, 42, 70, and 98. Body length was 731 
measured from the intermediate tubercale of the humerous (point of the shoulder) to the 732 
ischiatic tuberosity (point of the buttock). Girth circumference was measured 733 
immediately behind the slope of the wither, caudal to the elbow (olecranon tuber). 734 
Abdominal circumference was taken at two-thirds the distance from the intermediate 735 
tubercale of the humerous (point of the shoulder) the point of the hip (tuber coxae). 736 
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Horses were clipped in the areas where measurements were made initially to ensure later 737 
measurements were taken at the same location.  738 
 739 
Body Composition Measurements 740 
Rump fat thickness was measured using B-mode ultrasound (Sonovet 2000, 5mgHz) 741 
(Kearns et al., 2006a; Kearns et al., 2006b) on d 0, 14, 28, 42, 70, and 98. The site for 742 
measurement was determined by measuring half the distance from the point of the hip 743 
(tuber coxae) to the point of the buttock (ischiatic tuberosity); and half of the distance 744 
from this point to the spine. Scans were made on alternating sides so as not to be affected 745 
from healing biopsy sites. Body fat percentage was estimated using the following 746 
equation (Kane et al., 1987); Percent Fat = 2.47 + 5.47 (rump fat in cm). Fat mass was 747 
calculated by multiplying percent fat and total body mass. Fat free mass was determined 748 
by the difference between total body mass and fat mass. 749 
 750 
Circulating Oxidant Status Biomarkers 751 
Non-fasting blood samples (~35 mL) were collected via jugular venipuncture on d 0, 14, 752 
21, 28, 35, 42, 56, 70, and 98, placed into sodium heparin and EDTA vacutainers 753 
(Vacutainer, Franklin Lakes, NJ). Tubes were immediately placed on ice. The EDTA 754 
tube was centrifuged at 3000 x g for 15 min, while the sodium heparin tube was kept 755 
aside and used for erythrocyte isolation.  Plasma aliquots from the EDTA tube were 756 
removed and stored at -20° C until analysis.  757 
 758 
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Sodium heparin plasma aliquots were used for nitric oxide approximation via the 759 
measurement of total nitrate by a colorimetric kit (Nitric Oxide Kit, Bioassay Systems, 760 
Hayward, CA) including deproteination for all plasma samples following the kit 761 
instructions. Duplicate coefficient of variation was accepted as 10% or below.  762 
 763 
Erythrocytes were isolated following a protocol adapted from Lamprecht and Williams 764 
(Lamprecht and Williams, 2012). Briefly, 500 μL whole blood from a sodium heparin 765 
tube was transferred into a microcentrifuge tube, spun at 2500 x g for 5 min at 4° C, and 766 
the plasma supernatant was removed. Erythrocytes were then washed with 500 μL of 767 
0.9% sodium chloride solution and centrifuged again at the same speed, duration and 768 
temperature. The supernatant was discarded and 1 mL ice-cold distilled deionized water 769 
was added to lyse the cells. Erythrocyte lysate was stored at -80° C until analysis for 770 
reduced glutathione (GSSH) and glutathione peroxidase-1 (GPx-1). Both GSSH and 771 
GPx-1 were analyzed using commercially available kits (GSH-400 and GPx-340, Oxis 772 
Biomedical Research, Foster City, CA). Protocols on the kit insert were followed and 773 
sample volumes adjusted to produce repeatable results within the detectable range. The 774 
accepted coefficient of variation between duplicates was 10% for both assays. 775 
 776 
Muscle Biopsies 777 
Muscle biopsies were collected on d 0, 14, 28, 42, 70, and 98. Prior to biopsy sampling, 778 
biopsy sites were measured, clipped, and scrubbed with chlorhexadine solution followed 779 
by an isopropyl alcohol rinse. Horses were then lightly sedated with xylazine (0.5mg/kg 780 
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BW) and were administered 10 cc lidocaine anesthesia to the rump site. Consecutive 781 
samples were taken on alternating sides so as to allow sites to fully heal.  782 
 783 
Muscle biopsy site measurements were calculated by determining half the distance from 784 
the point of the hip (tuber coxae) to the point of the buttock (ischiatic tuberosity). From 785 
this point, a measurement was made to the spine, and biopsy site was placed at half this 786 
length, with preparations made as stated above (Andrews et al., 1993). A Bergstrom 787 
biopsy needle (6mm diameter, 10 cm total length) was used to access the middle gluteal 788 
muscle (Kline et al., 1987; Liburt et al., 2012), where 1 g of tissue was removed. Biopsy 789 
sites were stapled closed, and left to heal for 10 d. Weighed sample allocations were 790 
made for immediate mitochondrial isolation. 791 
 792 
Mitochondrial Subpopulation Isolation  793 
Muscle biopsies were blotted dry, weighed into 100 mg pieces and rinsed with ice-cold 794 
Chappel-Perry buffer in preparation for SSM and IFM isolation. Methods were followed 795 
in accordance to those used by Palmer and colleagues (Palmer et al., 1977b) with minor 796 
modifications (Dabkowski et al., 2010; Dabkowski et al., 2009; Dabkowski et al., 2008b). 797 
Briefly, the samples were homogenized 1:10 (wt/vol) in ice-cold Chappel-Perry buffer, 798 
containing (in mmol/L) 100 KCl, 50 MOPS, 5 MgSO47H2O, 1 EGTA, and 1ATP at pH 799 
7.4. Homogenates were centrifuged at 700 x g for 10 min and supernatant containing 800 
SSM was removed and centrifuged again at 10,000 x g for 10 min to yield the SSM 801 
fraction. A series of rinse and centrifugation at 10,000 x g for 10 min were conducted to 802 
obtain a clean SSM fraction, resuspended in 100 uL KCl-MOPS-EGTA buffer. The 803 
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remaining pellet from the 700 x g spin was resuspended in KCl-MOPS-EGTA buffer 804 
containing, in mmol/L, 100 KCl, 50 MOPS and 0.5 EGTA at pH 7.4 and exposed to 3.75 805 
mg/g trypsin for 7 min. After 7 min, the resuspended IFM were diluted twofold with 806 
buffer plus protease inhibitor cocktail (Biovision, Mountain View, CA) to inhibit further 807 
trypsin activity and centrifuged at 700 x g for 10 min. The IFM-supernatant was saved 808 
while the remaining pellet was resuspended in KCl-MOPS-EGTA buffer and spun down 809 
again at 700 x g for 10 min to maximize IFM yield. The IFM supernatants were 810 
combined and spun down at 10,000 x g for 10 min. After a series of wash steps, IFM 811 
were spun down at 10,000 x g for 10 min and the resulting pellet was resuspended in 100 812 
uL KCl-MOPS-EGTA buffer. Both populations were stored at -80° C until analysis.  813 
 814 
Complex Activities and ATP Synthase 815 
Electron transport chain complexes I, III, and IV activities were measured 816 
spectrophotometrically (Biotek Synergy HT plate reader, Biotek, Winooski, VT) on 817 
isolated frozen-thawed mitochondria as described by Dabkowski and colleagues 818 
(Dabkowski et al., 2010). Complex I activity was measured by the oxidation of NADH in 819 
the presence of an assay mixture containing 25 mM potassium phosphate buffer (pH 7.2), 820 
5mM MgCl2, 2mM KCN, 2.5 mg/mL bovine serum albumin, 50 μM NADH, 10 μM 821 
decylubiquinone, and 2 μg/mL antimycin A at 340 nm. The reaction was initiated at the 822 
addition of isolated skeletal muscle mitochondrial subpopulations, and enzyme activity 823 
was measured every 10s for 3 min. Complex I specific activity was inhibited by 2 μg/ mL 824 
rotenone. Complex III activity was quantified by measuring the reduction of cytochrome 825 
c at 550 nm. An assay buffer containing 2mM EDTA, 500 mM sucrose, 100 mM 826 
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Tris·HCl (pH 7.4), 1mM cytochrome c, 1 mg/mL antimycin A and reduced 827 
decycloubiquinone was combined with mitochondrial isolations and spectrophotometric 828 
measurements were made in 10 s increments for 3 min. Lastly, complex IV was measured 829 
by adding an assay mixture of 10 mM phosphate buffer (pH 7.4) and 20 μM reduced 830 
cytochrome c, where readings at 550 nm every 10 s for 3 min began at the addition of 831 
mitochondrial isolate determined oxidation of cytochrome c. Protein content was 832 
determined via the Bradford assay (Bradford, 1976) using bovine serum albumin as the 833 
standard. Values for complex activity data are expressed as nmol substrate consumed per 834 
min
 
per mg protein.  835 
 836 
ATP synthase activity was measured via approximation of maximal hydrolytic capacity 837 
of the enzyme in accordance with previously published methods (Dabkowski et al., 2010; 838 
Feniouk et al., 2007; Pullman et al., 1960; Rosca et al., 2009). Activity was measured 839 
spectrophotometrically via a coupled assay with lactate dehydrogenase and pyruvate 840 
kinase as coupling enzymes on frozen-thawed mitochondria as oligomycin-sensitive 841 
ATP-ase activity (Barrientos, 2002). Briefly, the mitochondria were incubated with a 842 
buffer containing, in mmol/L, 20 HEPES, 5 MgCl2, 100 KCl, 2.5 phosphoenolpyruvate, 843 
and 0.2 NADH, along with 0.1 mg/mL pyruvate kinase and 0.1 mg/mL lactate 844 
dehydrogenase, at combined pH of 7.5-8.0.  The reaction was initiated by adding ATP to 845 
a final concentration of 1 mM and followed by NADH reduction at 340 nm. Absorbance 846 
was monitored in 10 s increments for 3 min using a Biotek Synergy HT plate reader 847 
(Biotek, Winooski, VT). Protein content was measured as described above, with data 848 
 71 
expressed as μmol consumed per min per mg protein, which is equal to nmol of NADH 849 
oxidized per min per mg of protein.  850 
 851 
Citrate Synthase 852 
Citrate synthase activity was measured on frozen-thawed mitochondria utilizing the 853 
reaction 5’, 5’-Dithiobis 2-nitrobenzoic acid (DTNB) and CoA-SH to form TNB, as 854 
instructed by a commercially available kit (Citrate Synthase Activity, ScienCell Research 855 
Labroatories, Carlsbad, CA) (Morgunov and Srere, 1998; Trounce et al., 1996). The 856 
intensity of the absorbance of the assay at 412 nm is proportional to citrate synthase 857 
activity in the sample. As the assay was not completed on a fresh isolation, citrate 858 
synthase activity is used as a measure of total mitochondrial population in each isolation, 859 
rather than cleanliness of the isolation procedure. Data are expressed as activity/mg 860 
mitochondria. Mitochondrial content was measured by protein concentration assayed and 861 
calculated as stated above.  862 
 863 
Lipid Quantification and Peroxidation 864 
In order to estimate total lipid presence in mitochondrial isolations, a sulfo-phospho-865 
vanillin total lipid quantification procedure was conduced in accordance to previously 866 
published methods (Cheng et al., 2011). To summarize, each sample was diluted in a 2:1 867 
(v/v) chloroform:methanol mixture and allowed to fully evaporate. At this point, 100 μL 868 
concentrated sulfuric acid was added to each well, incubated at 90° C for 20 min, and 869 
allowed to cool at room temperature before reading for background absorbance at 540 nm 870 
(Biotek Synergy HT plate reader, Biotek, Winooski, VT). Then, 50 μL vanillin and 871 
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phosphoric acid mixture (0.2 mg/mL Vanillin in 17% phosphoric acid) were then added 872 
to each well and allowed to develop for 10 min before a final absorbance was read at the 873 
540 nm. The difference between the two readings was calculated and sample 874 
concentrations were calculated from a standard curve in μg/μL. 875 
 876 
Lipid peroxidation was assessed by the measurement of two stable end products, 877 
malondialdehyde (MDA) and 4-hydroxyalkenal (4-HAE), formed from the oxidation of 878 
polyunsaturated esters and fatty acids (Dabkowski et al., 2009; Dabkowski et al., 2008a). 879 
Frozen-thawed mitochondrial subpopulation isolations were analyzed for MDA and 4-880 
HAE using a commercially available colorimetric kit (Oxford Biomedical Research, 881 
Oxford, MI). In brief, this assay is conducted based upon the reaction of a chromogenic 882 
reagent, N-methyl-2-phenylindole, reagent 1, with MDA and 4-HAE at 45° C. One 883 
molecule of either MDA or 4-HAE reacts with one molecule of reagent 1 to yield a stable 884 
chromophore, detectable at 586 nm. Absorbance was measured on a Biotek Synergy HT 885 
plate reader (Biotek, Winooski, VT), where protein concentration allowed for equal 886 
sample loading. Final values are expressed per μg/μL total mitochondrial lipid.   887 
 888 
Statistical Analysis 889 
Data are expressed as mean ± SEM. Normality of all data were assessed prior to 890 
statistical analysis (SAS Institue, V9.3, Cary, NC). Any variable found to be non-891 
normally distributed by evaluation of kurtosis and skewness values, along with 892 
significance in tests for location (students t and sign tests) and normality (Shapiro-Wilk 893 
and Klomogorov-Smirinov tests) where p ≤ 0.05, were log10 transformed. The effect of 894 
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BCS change and percent weight loss was tested for all data using proc MIXED procedure 895 
of SAS with repeated measures. Gender, horse, age and date were included in the class 896 
statement during repeated measures analysis. Similarly, when evaluating complex I, III, 897 
IV, ATP synthase, citrate synthase and activities, along with lipid peroxidation, 898 
subpopulation was also included in the model and class. The model with the best fit 899 
according to Akaike’s Information Criterion used a compound symmetry structure. A 900 
Pearsons Correlation was run using the proc CORR procedure of SAS, with Bonferroni 901 
correction to prevent the incidence of type I errors when performing multiple 902 
comparisons. For all data except correlations p<0.05 was considered significant and 903 
trends were noted at p<0.10. Due to the bonferroni correction, p<0.0021 was considered 904 
significant and trends were noted when p<0.0052 for all correlations.  905 
 906 
Results 907 
Body and Morphometric Measurements 908 
Horses on the study transitioned from a mean BCS of 7.8 ± 0.02 a moderate body 909 
condition, 5.0 ± 0.0 during the course of the weight loss period. A summary of horse age, 910 
breed, sex and body characteristics are reported in table 1. Averages of body weight, girth 911 
circumference, abdominal circumference, RFT, percent fat, fat mass and fat free mass are 912 
reported in table 4.  913 
 914 
Circulating Oxidant Status Markers 915 
In relationship to change in body condition score, trends toward significance were 916 
displayed for decreasing nitrate concentration (p=0.06) and increasing reduced 917 
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glutathione concentration (p=0.07), while no differences were noted with regard to GPx 918 
(figure 1).  When analyzed in response to percent weight loss, glutathione and GPx were 919 
not significant but nitrate concentration retained a trend (p=0.06, figure 1 A-C).  920 
 921 
Electron Transport Chain Enzyme Activities, Citrate Synthase and Lipid Peroxidation 922 
Significant differences were found between mitochondrial subpopulations regarding 923 
decreasing complex I, and IV activity, while a trend was observed for complex III 924 
activity, where p=0.02, 0.001, and 0.06, respectively. Further, activity in complex I 925 
(p=0.01), III (p<0.0001) and IV (p=0.001) decreased in response to change in BCS. The 926 
interaction between mitochondrial subpopulation and change in body condition score was 927 
significant for complex IV (p=0.001), but not complexes I or III where IFM decreased 928 
with change in BCS but SSM did not. ATP synthase activity was not found to be 929 
significantly affected for any comparison or interaction. Data analysis for complexes I, III 930 
and IV in addition to ATP synthase are represented in figure 2 A-D. 931 
  932 
When complex enzyme activities were analyzed with respect to percent weight loss, 933 
complex I displayed a decrease in activity with regard to mitochondrial subpopulation 934 
(p=0.03) and percent weight loss (p=0.002), but no effect was denoted for the interaction 935 
(Figure 2A). Complex III displayed a significant reduction in activity in response to 936 
weight loss (p<0.0001), and a trend for differences between subpopulations (p=0.06) yet 937 
the interaction was not significant (Figure 2B). Subpopulation (p=0.003) and weight loss 938 
(p=0.01) caused a decrease in complex IV activity, further displayed by an interaction 939 
between these parameters (p=0.05, Figure 2C), signifying differential effects of weight 940 
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loss parameters on each subpopulation within this complex. No differences were found 941 
with regard to ATP synthase activity and any included model parameter (Figure 2D).  942 
 943 
As an approximate measure of mitochondrial number, citrate synthase activity was found 944 
to be different between subpopulations (p<0.0001) in both models where SSM showed a 945 
higher concentration than IFM, but no effect of change in body condition score, percent 946 
weight loss or appropriate interaction was observed (Figure 3).  947 
 948 
A significant effect of subpopulation (p=0.01) was observed where SSM displayed 949 
greater amounts of lipid peroxidation than IFM. Change in body condition and 950 
interactions between model components were observed for lipid peroxidation (p=0.01, 951 
0.004, and 0.05, respectively) where peroxidation levels decreased due to reduction in 952 
BCS. Similarly, when evaluated in response to weight loss, significance was observed 953 
between higher levels of peroxidation in the SSM and IFM mitochondrial subpopulations 954 
(p=0.02), and decreases in peroxidation due to percent weight loss (p=0.01), with a trend 955 
for significance displayed for the interaction (p=0.07 Figure 4). 956 
 957 
Correlations 958 
Body condition score was positively correlated to lipid peroxidation in the IFM 959 
(p=0.002). Complex III activity in the SSM (p<0.0001) and complex IV (p=0.0002) 960 
activity in the IFM showed a significant positive correlation to BCS. Similarly when 961 
correlating these variables to cresty neck score, significance was determined between 962 
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SSM complex III activity (p=0.002) and a trend was noted between IFM complex IV 963 
activity (p=0.003).   964 
 965 
Citrate synthase activity in the SSM was negatively correlated to complex IV in the same 966 
subpopulation (p=0.002). Further, citrate synthase activity between the subpopulations 967 
displayed a significant positive correlation (p<0.0001). Interfibrillar citrate synthase 968 
activity was significantly correlated to lipid peroxidation within the subpopulation 969 
(p<0.0001).  A summary of these and other correlation data can be found in table 5.  970 
 971 
Discussion 972 
Body composition is an important factor to consider when evaluating metabolic function, 973 
specifically with regard to glucose and lipid metabolism (Pedersen et al., 2003; Reaven, 974 
1995). Due to the subjective nature of the Henneke body condition scoring system along 975 
with wanting to examine changes in regional adiposity, we included morphometric 976 
measurements to provide a comprehensive picture of phenotypic body adipose deposits 977 
(Carter et al., 2009; Henneke et al., 1983); however, body composition can be 978 
challenging to measure in a live animal. The concurrent reduction in rump fat thickness 979 
with decreasing body weight suggests horses were loosing fat mass as they transitioned to 980 
a moderate body condition. Further, the reduction in fat free mass suggests that some 981 
portion of lean body tissues were utilized for energy homeostasis, consistent with 982 
metabolic processes during calorie restriction.  Although horses were enrolled in a light 983 
exercise program during the time of the study, horses were acclimated to this level of 984 
exercise; therefore, no skeletal muscle adaptation to workload was expected.  985 
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 986 
Skeletal muscle mitochondrial distribution is directly related to fiber type composition 987 
and therefore responses to physiological states can be altered depending on muscle fiber 988 
profile. In humans, metabolic disturbances associated with obesity and diabetes are 989 
associated with low percentages of type I fibers (Hickey et al., 1995). Further, mice 990 
engineered to have a high number of type I fibers are more insulin sensitive and less 991 
susceptible to diet-induced obesity (Ryder et al., 2003).  The middle gluteal muscle 992 
sampled during this study for mitochondrial evaluation reflects a mixed fiber type, where 993 
previous research shows at a depth of 6 cm type I slow oxidative fibers represent 26.7 ± 994 
5.9%, type IIa fast oxidative fibers characterize 54.9 ± 8.3% and type IIb fast glycolytic 995 
fibers comprise 18.4 ± 8.4%, respectively (Kline et al., 1987). Therefore, we expect the 996 
mitochondria isolated and analyzed in this study should reflect a mixed population and 997 
role within functioning muscle. The distribution signifies an equal ability to tolerate both 998 
aerobic and anaerobic respiration along with various energy substrates, thereby 999 
incorporating representative differences in weight loss across associated skeletal muscle 1000 
fiber responses  1001 
 1002 
Although it is recognized that skeletal muscle mitochondria exist together in a reticulum, 1003 
compartmentalization into SSM and IFM allow for differential effects of physiologic 1004 
intervention or disease states, and thus should be studied independently (Palmer et al., 1005 
1977a). For example, in mice subjected to streptozocin-induced type I diabetic insult, 1006 
cardiomyocytes displayed greater IFM than SSM dysfunction, whereas in a db/db type 2 1007 
diabetic model the SSM was more affected (Baseler et al., 2011; Dabkowski et al., 2010). 1008 
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The SSM provide energy for membrane related processes including signal transduction, 1009 
ion exchange, and substrate transport and substrate activation (Hood, 2001); metabolic 1010 
processes necessary for insulin signaling and glucose metabolism. The SSM evaluated in 1011 
this study did not display a large change in activity, and based on the relatively conserved 1012 
function of the SSM complex activities during weight loss, it is plausible that the SSM 1013 
played a role in the improved insulin sensitivity displayed in the aforementioned chapter. 1014 
As the SSM were not dysfunctional during weight loss, their function may have been 1015 
important to the modulation of the obese phenotype, reflected by the lack of change in 1016 
glucose mediated glucose disposal and other minimal model parameters. Currently, the 1017 
only available equine-related information has utilized activity of mitochondrial marker 1018 
enzymes such as succinate dehydrogenase or mitochondrial volume density to estimate 1019 
muscle oxidative capacity (Hoppeler et al., 1987; Kayar et al., 1989; Quiroz-Rothe and 1020 
Rivero, 2001; Snow and Guy, 1980), with no data describing the roles of subpopulations 1021 
on overall energy generation. In human and rodent obesity models, the SSM is primarily 1022 
affected, displaying greater levels of complex activities during weight loss or when obese 1023 
models are compared to a lean counterpart (Kelley et al., 2002a; Ritov et al., 2005; 1024 
Toledo et al., 2007). Previous work from our laboratory suggests equine skeletal muscle 1025 
mitochondria subpopulations may play a more equal role than that of rodents (Zambito et 1026 
al., 2013). The greater malleability of IFM function with relationship to complex I, III 1027 
and IV activity suggests that within the horse, this subpopulation may be more sensitive 1028 
to physiological states. 1029 
 1030 
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Further, results from this study display a decreasing maximal activity for complex I, III 1031 
and IV in obese horses transitioning through weight loss. These results are contrary to 1032 
most published research both relating to obesity-related, diabetic models, and weight loss 1033 
influences on mitochondrial dysfunction in rodents and humans (Bajpeyi et al., 2011; 1034 
Dabkowski et al., 2008a; Kelley et al., 2002b; Ritov et al., 2005; Toledo et al., 2007). 1035 
Thus far, little work has been completed evaluating equine mitochondrial function 1036 
(Votion et al., 2012) leaving many areas unclear with regard to species related differences 1037 
in mitochondrial adaptation to physiological change. The higher level of activity when 1038 
horses were at an obese body condition score may signify that the mitochondria 1039 
compensated for excess dietary nutrient influx, and thus were the foundation for the lack 1040 
of differences seen elsewhere. The flexibility of both populations of mitochondria, 1041 
specifically the IFM, could not only be an evolutionary advantage for the horse to alter 1042 
metabolic function in the face of differing nutritional status but also may tie into the 1043 
inherent exercise capability of the horse over many other species.  1044 
 1045 
In addition to their primary roles in substrate oxidation and ATP generation, 1046 
mitochondria are also a primary source of reactive oxygen species. Declining complex 1047 
activity should not necessarily be viewed as a negative result, as decreasing activity may 1048 
reduce reactive oxygen species production. As body condition decreases and percent 1049 
weight loss increases, nitrate levels as an indicator of nitric oxide decreases, while 1050 
glutathione concentration increases. Combined these data suggest that overall whole body 1051 
oxidant status was improving as horses lost weight. Glutathione peroxidase activity was 1052 
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not altered due to weight loss, yet it is plausible that the level of oxidative stress was not 1053 
elevated to the degree to impact enzyme activity.  1054 
 1055 
Lipid peroxidation decreased in both SSM and IFM, with a greater level of damage 1056 
observed in the SSM. As mentioned previously, electron transport chain complex I, III, 1057 
and IV activity displayed a greater decrease in the IFM, thus generation of reactive 1058 
species should decline in a similar manner. The resulting decrease in free radicals and 1059 
reactive oxygen species would explain the decrease in lipid peroxidation observed in the 1060 
IFM; a theory that could likewise be applied to the SSM. The higher level of lipid 1061 
peroxidation observed in the SSM may be a function of mitochondrial number, as 1062 
estimated by citrate synthase activity or position within the cell.  Location directly 1063 
beneath the plasma membrane may subject this population to oxidative insult from 1064 
circulating oxidant species along with reactive oxygen species produced from the SSM 1065 
alone. 1066 
 1067 
Further, the possibility remains that due to high volume of oxidative phosphorylation 1068 
capacity reflected by the nearly 50-fold increase from resting to maximal VO2 (Poole, 1069 
2004), horses may have adapted to tolerate higher levels of oxidative stress. Splenic 1070 
contraction is a unique performance advantage to the horse (Poole, 2004) and even in an 1071 
obese horse model and from an evolutionary perspective they still must retain a certain 1072 
level of athletic ability despite a greater fat mass. The ability to tolerate high oxygen 1073 
concentrations in the muscle without excessive oxidative damage may prove to be 1074 
beneficial in the instance of obesity-induced increases in oxidant status. Further, if the 1075 
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mitochondria had increased function to cope with an excess substrate load, the reduction 1076 
in activity would signify return to a normal level of operation. Comparison of basal 1077 
metabolic rates between mean obese and moderate BCS weights display a reduction from 1078 
18 Mcal/d to 16 Mcal/d, as calculated by body weight (kg)
0.75
 x 115 kcal. Decreased 1079 
basal metabolic rate could also result in a lower complex activities and an overall 1080 
reduction in oxidant status. Without supplemental data and analysis of the mechanisms 1081 
behind mitochondrial function in the horse, exact understanding of these changes remains 1082 
unanswered. 1083 
 1084 
In conclusion, data suggest equine skeletal muscle mitochondrial subpopulations in this 1085 
study contradict central dogma in human and rodent models regarding obesity- and 1086 
weight loss-related influences on SSM and IFM function. The degree of obesity achieved 1087 
prior to weight loss was adequate to induce increases in complex activity, and oxidant 1088 
status within the body, yet not to the degree to transition into a metabolic disease state. 1089 
Additional studies are warranted to not only elucidate mechanisms behind mitochondrial 1090 
malleability in the equine model but also to fully determine the impact of mitochondrial 1091 
function on exercise capacity.  1092 
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Tables and Figures 1103 
Table 1: Summary of individual horse characteristics  1104 


















1 10 M Quarter Horse 142.2 157.5 71.1 
2 6 M Tennessee Walker 148.0 137.2 71.1 
3 13 M Standardbred 160.0 156.2 101.6 
4 19 G Quarter Horse 149.9 149.9 86.4 
5 5 M Quarter Horse 147.3 152.4 81.3 
6 10 G Quarter Horse 170.8 165.1 96.5 
7 19 M Quarter Horse 151.8 158.8 95.3 
8 15 M Quarter Horse 157.5 165.1 104.1 
   
Mean ± SEM 153.4 ± 3.2 155.3 ± 3.3 88.4 ± 4.6 
1 
For sex categorization M represents mare and G represents gelding.  1105 
2
 Measured from the ground to the highest point of the wither 1106 
3
 Measured from the point of the shoulder to the point of the rump 1107 
4
 Measured from the poll to the point of union between neck musculature and the wither 1108 
 1109 
 1110 
  1111 
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Table 2: Nutrient analysis of grass hay and concentrate, as fed 1112 
Nutrient, as fed Grass Hay Concentrate 
Dry Matter (%) 95.8 93.4 
Digestable Energy (DE,  Mcal/kg) 1.85 2.84 
Crude Protein (g/kg) 51.5 150.1 
Acid Detergent Fiber (ADF, g/kg) 371.8 166 
Neutral Detergent Fiber (NDF, g/kg) 625.8 330.8 
Water Soluble Carbohydrates (WSC, g/kg) 56.0 89.4 
Ethanol Soluble Carbohydrates (ESC, g/kg) 15.5 51.7 
Starch (g/kg) 14.3 131.4 
Non-fiber Carbohydrates (NFC, g/kg) 156.8 350.9 
Crude Fat (g/kg) 28.6 59.3 
Calcium (g/kg) 6.03 12.91 
Phosphorus (g/kg) 0.83 8.15 
Sodium (g/kg) 0.218 2.369 
 1113 
Table 3: Percent composition of diet on a dry matter basis 1114 
Nutrient, % dry matter Grass Hay Concentrate 
Crude Protein, % 5.4 16.1 
Acid Detergent Fiber, % 38.8 17.8 
Neutral Detergent Fiber, % 65.4 35.4 
Water Soluble Carbohydrates, % 5.9 9.6 
Ethanol Soluble Carbohydrates, % 1.6 5.5 
Starch, % 1.5 14.1 
Non-fiber Carbohydrates, % 16.4 37.6 
Crude Fat, % 3 6.3 
Calcium, % 0.63 1.38 
Phosphorus, % 0.09 0.87 
Sodium, % 0.023 0.254 
 1115 
 1116 
  1117 
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End Weight Loss Period
2
 
Mean SEM Mean SEM 
Weight (kg) 547.3 4.9 487.0 8.4 
Body Condition Score
3
 7.8 0.02 5.0 0.00 
Girth Circumference (cm)
4
 194.9 0.6 188.3 1.2 
Abdominal Circumference (cm)
5
 213.6 0.7 199.7 1.9 
Rump Fat Thickness (mm)
6
 11.2 0.2 5.3 0.2 
Percent Fat
7
  8.6 0.1 5.3 0.1 
Fat Mass (kg)
8
 46.7 0.7 27.3 0.9 
Fat Free Mass (kg)
9
 500.6 4.6 456.9 8.1 
 1120 
1
 Reported measurements taken on d14 as horses exited the baseline sampling period 1121 
2
 Reported measurements taken on d 98 as horses exited the study 1122 
3
 Assessment based on a 1-9 scale (Henneke et al., 1983) 1123 
4
 Measured immediately behind slope of wither, caudal to elbow 1124 
5
 Measured at two thirds distance from point of shoulder to point of hip 1125 
6
 Measured by B-mode ultrasound, site determined by measuring half the distance from 1126 
the point of the hip (tuber coxae) to the point of the buttock (ischiatic tuberosity); and 1127 
half of the distance from this point to the spine, units expressed in cm 1128 
7
 Percent fat = 2.47 + (5.47 x rump fat thickness in cm) 1129 
8
 Fat mass = percent fat x body weight 1130 
9
 Fat free mass = body weight – fat mass 1131 
  1132 
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Figure 1 A-C: Changes in circulating oxidant status markers in relationship to change in 1133 
body condition score and weight loss.  Horses (n = 8) were enrolled in a baseline-1134 
sampling period lasting from d0 to d14, followed by a caloric restriction from d15 to d98, 1135 
where from d15 to d43 horses received a 30% digestible energy reduction, and from d44 1136 
to d 98 horses received a 30% restriction from maintenance digestible energy. On d 0, 14, 1137 
21, 28, 42, 56, 70, and 98, blood samples were collected and analyzed for plasma nitrate 1138 
concentration, erythrocyte glutathione concentration and erythrocyte glutathione 1139 
peroxidase activity. The main effect of change in body condition score (BCS) and percent 1140 
weight loss were analyzed for each variable, with data points representing values at 1141 















Figure 2A-D: Mitochondrial Subpopulation Electron Transport Chain Enzyme Activities 1152 
in Response to Change in Body Condition Score or Percent Weight Loss. Horses (n = 8) 1153 
were enrolled in a baseline-sampling period lasting from d0 to d14, followed by a caloric 1154 
restriction from d15 to d98, where from d15 to d43 horses received a 30% digestible 1155 
energy reduction, and from d44 to d 98 horses received a 30% restriction from 1156 
maintenance digestible energy. On d 0, 14, 28, 42, 70, and 98, middle gluteal muscle 1157 
biopsies were taken and mitochondrial subpopulations isolated through differential 1158 
centrifugation. Complex activities were measured spectrophotometrically depending on 1159 
substrate production from each complex. The main effect of change in body condition 1160 
score (BCS) and percent weight loss were analyzed for each variable, with data points 1161 
representing values at corresponding points of BCS change or weight loss, respectively. 1162 













  1171 
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Figure 3: Mitochondrial subpopulation citrate synthase activity as an indicator of 1172 
population size in response to change in body condition score or percent weight loss. 1173 
Mitochondrial Subpopulation Electron Transport Chain Enzyme Activities in Response 1174 
to Change in Body Condition Score or Percent Weight Loss. Horses (n = 8) were enrolled 1175 
in a baseline-sampling period lasting from d0 to d14, followed by a caloric restriction 1176 
from d15 to d98, where from d15 to d43 horses received a 30% digestible energy 1177 
reduction, and from d44 to d 98 horses received a 30% restriction from maintenance 1178 
digestible energy. On d 0, 14, 28, 42, 70, and 98, middle gluteal muscle biopsies were 1179 
taken and mitochondrial subpopulations isolated through differential centrifugation. 1180 
Citrate synthase activity was measured spectrophotometrically. The main effect of 1181 
change in body condition score (BCS) and percent weight loss were analyzed for each 1182 
variable, with data points representing values at corresponding points of BCS change or 1183 
weight loss, respectively. Shading indicates confidence intervals. 1184 
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Figure 4: Lipid peroxidation in mitochondrial subpopulations in response to change in 1186 
body condition score or percent weight loss. Horses (n = 8) were enrolled in a baseline-1187 
sampling period lasting from d0 to d14, followed by a caloric restriction from d15 to d98, 1188 
where from d15 to d43 horses received a 30% digestible energy reduction, and from d44 1189 
to d 98 horses received a 30% restriction from maintenance digestible energy. On d 0, 14, 1190 
28, 42, 70, and 98, middle gluteal muscle biopsies were taken and mitochondrial 1191 
subpopulations isolated through differential centrifugation. Mitochondrial lipid 1192 
peroxidation was measured spectrophotometrically, and was normalized to total lipid 1193 
content determined via a sulfo-phosphovanillin assay. The main effect of change in body 1194 
condition score (BCS) and percent weight loss were analyzed for each variable, with data 1195 
points representing values at corresponding points of BCS change or weight loss, 1196 
respectively. Shading indicates confidence intervals. 1197 
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Table 5: Correlation of Morphometric Measurements, Complex Activity and Circulating 1199 
Oxidant Status Markers
1





P values reflect significance and trends identified with bonferroni corrections, where 1204 
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CHAPTER IV: LIMITATIONS 1217 
As with any research project, limitations are inherently present and must be considered 1218 
when interpreting results and looking forward to future research ideas. Specifically with 1219 
regard to this project, limitations included sample size, time of sampling, species specific 1220 
challenges, location of the project relative to analysis, and body condition of the subjects.  1221 
 1222 
Inclusion criteria for this study resulted in a relatively small sample size relative to initial 1223 
expected subject number. Upon analysis of results, specifically from both mitochondrial 1224 
complex activities and minimal model output, large individual variation was observed. 1225 
While consideration was taken to account for variability caused by gender, age, date and 1226 
subpopulation where appropriate, additional comparisons may have been made had there 1227 
been a larger total sampling population. For example, in the current study horses 1228 
displayed a wide range of percent weight loss within observed BCS; had a larger sample 1229 
size been possible, a natural break between “high” and “low” percentages of weight loss 1230 
may have been revealed. The possibility remains that information regarding metabolic 1231 
alterations with regard to weight loss is masked behind large variation. Increasing the 1232 
sample size and allocating for natural breaks within the population could lend explanation 1233 
to the variation observed in this study and alter overall interpretation of changes 1234 
associated with obesity and subsequent weight loss.  1235 
 1236 
Labor limitations and available stall space were also of concern during this study. All 1237 
possible means to ensure horses were fed, managed and sampled in the same manner 1238 
were taken, yet it was not fesable to collect fasting blood samples for analysis of 1239 
 95 
circulating metabolic indicators. Since samples were collected post-prandially, results 1240 
were inconclusive. As the baseline FSIGT samples were collected after an overnight fast, 1241 
we elected to evaluate these samples for circulating NEFA and TG levels (insulin and 1242 
glucose concentrations measured for minimal model analysis). Unfortunately due to the 1243 
timing of each FSIGT, this only provides for beginning and end-point information on 1244 
these markers, leaving out samples from the weight loss period. Looking forward, 1245 
management of horses so that fasting samples can be collected should be discussed for 1246 
feasibility prior to the start of the research project. Additionally, inclusion of other 1247 
markers that are not affected by fasting or fed states, including hemoglobin A1C or other 1248 
glycosylated end products may also be of interest if fasting samples cannot be collected.  1249 
 1250 
Unfortunately, while working with livestock species many analysis procedures do not 1251 
transfer easily. For example, while hemoglobin A1C is considered a valid method for 1252 
analyzing advancement of hyperglycemia in humans and rodents, initial attempts at 1253 
transferring procedures to the horse have produced variable data. Additionally with 1254 
regard to this study, measurement of specific oxidant status markers such as hydrogen 1255 
peroxidase, manganese and copper/zinc superoxide dismutase have proven difficult to 1256 
analyze with repeatable results. Analysis of genetic messages has also proven difficult, as 1257 
the equine genome is not well annotated and many gene sequences are either unavailable 1258 
or predicted. Thus, the measurements reported in this manuscript reflect assays 1259 
previously validated in the horse. Further work is needed to accurately transition the 1260 
aforementioned and other methodologies for analysis on equine samples.  1261 
 1262 
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In addition to the species-specific confines present in this study, travel limitations placed 1263 
further restrictions on sample analysis procedures. As all samples were collected in 1264 
Murfreesboro, TN and analysis was completed in Morgantown, WV samples were frozen 1265 
at either -20 or -80 ° C until transport and measurement was completed.  Many 1266 
measurements to analyze mitochondrial number, size, respiration and functionality must 1267 
be completed on fresh, not frozen, isolations. Moreover, analysis of complex II activity 1268 
requires fresh mitochondria and therefore was not feasibly possible during this study. 1269 
Looking forward, consideration should be given to alternate methods of sampling or 1270 
locations in order to fully analyze mitochondrial parameters.  1271 
 1272 
As previously mentioned, horses were body condition scored prior to entry into the study. 1273 
While we did account for overall obesity by using this method, hindsight suggests we 1274 
should have also taken CNS into account. The horses on this project had CNS ranging 1275 
between 2.5 to 3 during the baseline sampling period, which is considered a moderate 1276 
score.  Selecting horses with a CNS score of 3.5 or greater, it is possible we would have 1277 
observed different results as horses would have been more obese. Further, as amount of 1278 
neck crest fat can signify a transition into an unhealthy metabolic state (Carter et al., 1279 
2009), selecting horses with higher CNS could provide insight into the transition from 1280 
“metabolically healthy obese” to “metabolically unhealthy”. Degree of adiposity in the 1281 
neck crest region should be considered when designing future studies, especially if 1282 
metabolic dysfunction is to be evaluated.  1283 
  1284 
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CHAPTER IV: OVERALL IMPLICATIONS, CONCLUSIONS 1285 
AND FUTURE DIRECTIONS  1286 
 1287 
Obesity in the equine industry has continued to increase over time, without predisposition 1288 
for breed, discipline or region. Viable information regarding the progression of metabolic 1289 
changes associated with equine obesity and subsequent weight loss are critical to proper 1290 
management and understanding of species-specific metabolic processes. Knowledge 1291 
gained from this study has the capacity to influence not only nutritional interventions but 1292 
also catalyze the industry’s interpretation of equine performance and evolutionary 1293 
advantages.  1294 
 1295 
Evaluation of circulating biomarkers suggests horses were beginning to show signs of 1296 
metabolic alterations as signified by the elevated nitrate and reduction in reduced 1297 
glutathione concentrations. Combined with the lack of changes seen in most minimal 1298 
model parameters, it is hypothesized that horses were metabolically healthy despite their 1299 
obesity. Although cellular dysfunction is typically reflected in circulating markers, it is 1300 
plausible that obesity-related metabolic changes were in the primary stages of 1301 
development. Insulin sensitivity displayed improvements with weight loss, signifying 1302 
some alteration in signaling or sensitivity at the tissue level, yet AIRg was not affected. 1303 
Had a more advanced stage of obesity been allowed to develop, it is suspected that more 1304 
advanced dysfunction would have developed. This  “metabolically healthy obese” 1305 
phenotype may be very delicate, easily transforming into a disease state, yet providing 1306 
some insight as to compensatory mechanisms behind the commonly accepted 1307 
dysfunctions associated with excessive adipose deposition. 1308 
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 1309 
Equine mitochondria is surprisingly unstudied, especially due to the competitive athletic 1310 
nature of the equine industry. Based on the results of this study, it is evident that a 1311 
species-related difference in coping mechanisms are present in the horse when directly 1312 
compared to the human or rodent models.  It is commonly regarded that horses provide 1313 
an excellent model for human exercise performance and to a certain extent this theory 1314 
remains true. While horses display a similar thermoregulatory system to that of a human, 1315 
it is well known that horses possess numerous physiological adaptations contributing to 1316 
their superior athletic ability. Without excessive speculation, it is feasible that the 1317 
mitochondria also play a significant role in the performance of the equine athlete. 1318 
Respiration levels of SSM and IFM from equine middle gluteal muscle compared to 1319 
gastrocnemius and soleus mitochondrial subpopulation isolations C57/Black 6 displayed 1320 
similar activity levels, yet substrate utilization time was much faster for both equine 1321 
populations (Zambito et al., 2013).  1322 
 1323 
When combined with the data shown from this project, it is even more evident that horses 1324 
display unique physiological mechanisms with respect to mitochondrial function. As 1325 
horses are known for their ability to naturally blood dope via splenic contraction, the 1326 
mitochondria may possess the ability to better handle large amounts of oxygen delivery 1327 
without subsequent oxidative damage. This inherent protection may allow for equine 1328 
mitochondria to possess more malleable characteristics to tolerate altering physiological 1329 
environments. Return to a nearly equal level of complex activity between SSM and IFM 1330 
displayed in this data could signify a more equal role between mitochondrial 1331 
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subpopulations in a healthy state; a theory vastly differing from the suggested roles of 1332 
SSM and IFM in humans and rodents alike (Kelley et al., 2002b; Menkishova et al., 1333 
2006; Ritov et al., 2005; Toledo et al., 2007).  Unfortunately, due to lack of research on 1334 
this specific topic, many of the proposed conclusions are based off negative comparisons 1335 
with data in other species and not from completed works within the equine population. 1336 
Mitochondrial research has an incredible depth of untapped potential due to the 1337 
application of the knowledge base to athletic performance, cloning and reproduction and 1338 
general animal health. Much more work is needed in this area to fill in the missing pieces 1339 
as to the unique qualities of equine mitochondria.  1340 
 1341 
Overall, it is evident that differences within the obese horse population exist between 1342 
those considered metabolically healthy and those displaying signs of severe metabolic 1343 
impairment. Excessive fat deposition in specific regions, including the neck crest and 1344 
abdomen, may require more attention when determining how to manage and care for 1345 
obese horses. From a scientific standpoint, the central dogma surrounding overweight 1346 
horses and the incidence of metabolic dysfunction may need to be re-evaluated with 1347 
regard to physiological factors and onset of disease states.  1348 
 1349 
Looking forward, much work is needed with regard to mitochondrial function and obesity 1350 
related metabolic changes in the horse. Classification of healthy equine mitochondria is 1351 
necessary to understand not only the role of mitochondria on athletic performance but 1352 
also propagation of disease states. Based on research in other species it remains plausible 1353 
that understanding of many equine-related diseases can lie in evaluation of mitochondrial 1354 
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function. Also, as regional fat deposition appears to play a role in obesity-related 1355 
metabolic dysfunction research is needed to determine rates of deposition in different 1356 
areas and their relationship to overall metabolism. Lastly, an in depth evaluation of the 1357 
presence of a “metabolically healthy obese” phenotype is needed to classify how the 1358 
industry manages obese horses. By understanding the physiology behind obesity related 1359 
changes in glucose and lipid metabolism can drastically alter how we view the 1360 
obese/overweight horse in both the performance and recreational setting.  1361 
  1362 
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Boots 0 4.57 21.56 0.0076 0.483 12.22 108.69 2.80 
Boots 14 7.52 14.09 0.0090 0.188 21.98 127.07 4.82 
Boots 21 7.48 20.56 0.0108 0.192 34.22 126.09 4.45 
Boots 28 11.87 18.51 0.0116 0.306 24.72 108.87 3.69 
Boots 35 22.57 12.81 0.0152 0.124 38.44 133.17 5.27 
Boots 42 16.17 15.34 0.0190 0.354 22.98 111.04 7.18 
Boots 56 11.97 11.95 0.0135 0.114 17.46 127.33 2.38 
Boots 70 24.89 26.44 0.0064 0.276 34.68 95.91 2.39 
Boots 98 4.00 13.06 0.0177 0.240 10.32 114.81 2.68 
Daphne 0 20.76 8.61 0.0175 0.075 18.48 113.65 12.70 
Daphne 14 14.27 10.02 0.0109 0.074 46.32 91.63 6.16 
Daphne 21 16.52 12.12 0.0159 0.297 20.84 104.55 4.62 
Daphne 28 12.48 9.98 0.0182 0.157 18.1 112.52 5.04 
Daphne 35 10.01 8.36 0.0119 0.451 149.32 122.64 4.47 
Daphne 42 5.40 9.86 0.0187 0.131 18.4 107.54 6.55 
Daphne 56 15.43 8.62 0.0109 0.114 31.46 143.55 3.31 
Daphne 70 10.25 14.26 0.0083 0.094 21.7 134.84 7.27 
Daphne 98 5.18 12.06 0.0121 0.239 35.94 133.27 9.22 
Getda 0 18.33 13.56 0.0100 0.575 18.46 96.39 3.88 
Getda 14 15.92 12.31 0.0087 0.080 22.42 118.05 17.82 
Getda 21 21.84 14.27 0.0087 0.258 25.7 93.51 2.47 
Getda 28 16.29 10.07 0.0134 0.316 26.34 151.36 1.84 
Getda 35 8.39 14.29 0.0162 0.432 38.82 99.73 3.16 
Getda 42 16.14 10.87 0.0080 0.413 22.92 121.79 3.15 
Getda 56 49.56 17.00 0.0112 0.113 29.84 125.06 2.57 
Getda 70 8.75 30.38 0.0094 0.248 31.22 194.11 2.23 
Getda 98 10.33 30.38 0.0121 0.057 13.22 101.26 8.76 
JR 0 6.08 12.11 0.0091 0.073 27.82 110.82 1.99 
JR 14 6.21 11.76 0.0179 0.172 45.86 112.26 1.97 
JR 21 3.74 11.73 0.0116 0.157 33.6 97.53 3.71 
JR 28 4.66 7.79 0.0224 0.157 39.06 79.35 2.02 
JR 35 4.41 7.16 0.0163 0.182 29.06 43.48 2.02 
JR 42 4.98 6.79 0.0090 0.265 26.68 108.36 2.27 
JR 56 16.15 6.40 0.0107 0.073 17.34 99.85 2.31 



























Pistol 0 8.56 12.42 0.0115 0.176 8.04 97.36 4.09 
Pistol 14 10.59 10.85 0.0148 0.064 15.22 161.46 7.09 
Pistol 21 13.91 13.39 0.0077 0.144 20.22 108.73 3.52 
Pistol 28 7.53 11.78 0.0196 0.072 16.72 103.97 4.46 
Pistol 35 18.12 13.49 0.0211 0.179 23.18 100.17 2.77 
Pistol 42 6.53 12.47 0.0173 0.170 28.82 108.79 5.20 
Pistol 56 6.71 11.48 0.0159 0.068 19.68 128.33 2.98 
Pistol 70 8.21 21.88 0.0087 0.253 30.82 126.45 6.11 
Pistol 98 11.28 12.84 0.0234 0.158 15.96 145.46 8.29 
Romeo 0 20.57 14.14 0.0159 0.184 26.06 113.14 6.99 
Romeo 14 11.83 14.37 0.0199 0.073 23.72 152.51 11.42 
Romeo 21 13.79 23.06 0.0170 0.291 31.96 116.67 4.12 
Romeo 28 19.02 18.08 0.0155 0.318 30.96 74.13 2.23 
Romeo 35 13.84 11.00 0.0114 0.389 35.56 114.11 2.74 
Romeo 42 15.48 10.22 0.0196 0.198 27.2 117.78 3.35 
Romeo 56 25.70 10.01 0.0108 0.223 33.58 148.08 2.61 
Romeo 70 9.59 16.46 0.0149 0.154 38.04 136.13 1.62 
Romeo 98 6.83 13.80 0.0126 0.116 22.84 151.83 3.22 
Susie 0 9.88 7.76 0.0165 0.127 11.82 99.98 7.08 
Susie 14 10.23 11.74 0.0185 0.044 17.58 115.04 8.46 
Susie 21 18.26 12.95 0.0131 0.234 19.96 38.89 5.99 
Susie 28 14.32 9.72 0.0178 0.163 22.96 106.75 4.06 
Susie 35 13.94 10.55 0.0111 0.119 13.98 91.01 5.00 
Susie 42 17.87 12.29 0.0191 0.206 10.3 107.77 5.31 
Susie 56 14.33 10.36 0.0179 0.061 22.44 102.77 6.31 
Susie 70 12.87 16.35 0.0084 . 25.84 129.14 5.86 
Susie 98 5.25 15.00 0.0071 0.125 30.7 111.20 5.53 
Sweetie 0 18.99 11.33 0.0130 0.149 29.18 104.77 9.02 
Sweetie 14 6.91 9.61 0.0094 0.131 29.98 107.61 19.05 
Sweetie 21 22.88 9.61 0.0051 0.255 30.82 139.30 7.06 
Sweetie 28 6.98 14.29 0.0112 0.273 42.96 125.60 8.49 
Sweetie 35 3.69 11.16 0.0134 0.106 22.72 96.55 7.51 
Sweetie 42 6.21 9.20 0.0175 0.060 22.22 118.33 5.82 
Sweetie 56 6.70 9.74 0.0106 0.107 26.1 95.12 6.53 
Sweetie 70 11.40 17.07 0.0127 0.225 23.2 147.66 2.45 
Sweetie 98 5.74 11.03 0.0064 0.228 22.72 131.99 3.37 
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Boots 1 10 M Quarter Horse 142.2 157.5 71.1 
Daphne 2 6 M Tennessee Walker 148.0 137.2 71.1 
Getda 3 13 M Standardbred 160.0 156.2 101.6 
JR 4 19 G Quarter Horse 149.9 149.9 86.4 
Pistol 5 5 M Quarter Horse 147.3 152.4 81.3 
Romeo 6 10 G Quarter Horse 170.8 165.1 96.5 
Susie 7 18 M Quarter Horse 151.8 158.8 95.3 
Sweetie 8 15 M Quarter Horse 157.5 165.1 104.1 














at 0.25 NL 
(cm) 
Neck Circ. 
at 0.5 NL 
(cm) 
Neck Circ. 
at 0.75 NL 
(cm) 
Boots 0 187.96 208.28 10.16 77.47 95.25 110.49 
Boots 14 189.23 200.66 10.16 78.40 88.90 109.22 
Boots 28 187.50 201.00 10.00 73.50 89.00 104.00 
Boots 42 184.00 195.00 10.00 73.00 89.00 105.00 
Boots 70 182.00 190.00 8.00 74.50 90.00 106.00 
Boots 98 179.00 187.00 7.50 70.00 90.00 103.00 
Daphne 0 184.15 196.85 12.07 72.39 91.66 106.64 
Daphne 14 189.00 198.00 12.00 76.00 90.00 105.00 
Daphne 28 184.00 191.00 11.50 73.00 90.00 112.50 
Daphne 42 189.00 189.00 11.50 72.00 91.00 103.00 
Daphne 70 183.00 190.00 10.00 78.00 92.00 107.00 
Daphne 98 183.00 188.00 9.00 71.00 85.00 101.00 
Getda 0 201.93 226.06 11.43 79.38 102.24 118.75 
Getda 14 202.00 217.00 12.00 77.50 101.40 117.00 
Getda 28 206.50 219.50 . 76.00 92.00 107.50 
Getda 42 202.00 216.50 9.25 76.00 87.50 105.00 
Getda 70 220.50 221.50 8.50 74.00 93.50 104.00 
Getda 98 . . 7.00 72.00 91.50 102.00 
JR 0 189.23 215.90 13.97 79.38 102.87 123.19 
JR 14 187.00 213.00 15.24 78.00 91.00 113.00 
JR 28 184.00 208.00 13.00 80.00 90.50 116.00 
JR 42 182.00 286.00 10.00 78.00 91.00 110.00 
JR 70 186.00 199.00 10.00 78.00 105.00 119.00 
Pistol 0 186.69 208.28 10.80 69.85 91.44 109.22 
Pistol 14 187.00 196.00 10.00 83.00 105.00 113.00 
Pistol 28 189.00 203.00 9.00 68.50 93.00 107.00 
Pistol 42 187.00 200.00 9.00 76.00 97.00 107.00 
Pistol 70 179.50 182.50 10.00 73.50 85.50 106.00 
Pistol 98 187.50 196.00 5.50 76.00 90.50 106.00 
Romeo 0 212.09 231.14 12.07 87.00 106.68 125.73 
Romeo 14 218.00 230.00 12.00 89.00 104.50 125.50 
Romeo 28 210.00 233.00 11.00 89.00 104.00 128.00 
Romeo 42 214.50 225.50 10.50 85.50 102.00 124.00 
Romeo 70 208.00 228.00 9.00 82.00 98.00 127.00 














at 0.25 NL 
(cm) 
Neck Circ. 
at 0.5 NL 
(cm) 
Neck Circ. 
at 0.75 NL 
(cm) 
Susie 0 194.31 220.98 12.07 79.38 102.87 120.02 
Susie 14 191.77 224.79 13.97 76.84 102.87 120.02 
Susie 28 196.00 207.00 10.00 84.00 94.50 109.00 
Susie 42 188.00 213.00 . 76.00 94.00 103.00 
Susie 70 188.00 210.00 11.00 78.00 103.00 116.00 
Susie 98 182.50 208.00 6.50 75.50 92.50 113.00 
Sweetie 0 200.66 213.36 13.97 85.09 111.13 129.86 
Sweetie 14 196.85 217.17 13.97 81.92 109.22 129.54 
Sweetie 28 195.50 205.50 11.50 80.00 99.50 114.50 
Sweetie 42 196.00 207.00 9.00 82.00 100.00 121.00 
Sweetie 70 199.00 199.00 12.00 78.00 106.00 132.00 
Sweetie 98 197.00 195.00 6.00 77.50 90.00 108.00 
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Boots 0 8 3 9 7.39 36.4 455.9 492.3 
Boots 14 8 3 8 6.85 34.9 474.2 509.1 
Boots 28 8 3 8 6.85 33.0 449.3 482.3 
Boots 42 8 3 9 7.39 35.5 444.1 479.5 
Boots 70 6.5 2.5 7.5 6.57 30.3 430.6 460.9 
Boots 98 5 2 3 4.11 18.3 427.1 445.5 
Daphne 0 8 3 19 12.86 55.6 376.7 432.3 
Daphne 14 8 3 19 12.86 55.4 375.1 430.5 
Daphne 28 8 3 18 12.32 52.9 376.6 429.5 
Daphne 42 8 3 18 12.32 52.1 371.1 423.2 
Daphne 70 7 2.5 7 6.30 29.3 435.3 464.5 
Daphne 98 5 2.5 10 7.94 32.7 378.7 411.4 
Getda 0 8 2.5 5 5.21 30.1 547.7 577.7 
Getda 14 8 2.5 10 7.94 45.5 527.3 572.7 
Getda 28 7.5 2.5 9 7.39 41.6 521.5 563.2 
Getda 42 7.5 2 6 5.75 32.0 524.8 556.8 
Getda 70 5.5 2 3 4.11 22.9 533.9 556.8 
Getda 98 5 2 3 4.11 21.9 511.7 533.6 
JR 0 8 2.5 10 7.94 42.4 492.1 534.5 
JR 14 7 2.5 8 6.85 35.5 482.7 518.2 
JR 28 6.5 2 11 8.49 42.7 460.1 502.7 
JR 42 6 2 8 6.85 34.0 463.2 497.3 
JR 70 5 2 4 4.66 22.4 457.6 480.0 
Pistol 0 7 2.5 9.5 7.67 37.8 455.0 492.7 
Pistol 14 7.5 2.5 10 7.94 38.4 445.7 484.1 
Pistol 28 7.5 . 11 8.49 41.5 448.0 489.5 
Pistol 42 7.5 2.5 8 8.49 41.3 445.1 486.4 
Pistol 70 6.5 2.5 12 9.03 37.6 378.3 415.9 
Pistol 98 5 2 6.5 6.03 28.3 441.7 470.0 
Romeo 0 8 2.5 12 9.03 62.3 627.3 689.5 
Romeo 14 8 2.5 14 10.13 70.4 625.0 695.5 
Romeo 28 7.5 2.5 8 6.85 46.1 627.1 673.2 
Romeo 42 7.5 2.5 9 7.39 49.5 620.5 670.0 
Romeo 70 5.5 2 9 7.39 45.5 570.0 615.5 
Romeo 98 5 2 6.5 6.03 39.4 615.1 654.5 
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Susie 0 7.5 2.5 10 7.94 43.3 502.1 545.5 
Susie 14 7.5 2.5 10 7.94 43.0 498.4 541.4 
Susie 28 7 2.5 9 7.39 40.0 500.9 540.9 
Susie 42 7 2.5 8.5 7.12 38.0 495.6 533.6 
Susie 70 6.5 2 8 6.85 36.1 490.8 526.8 
Susie 98 5 2 10 7.94 40.6 470.3 510.9 
Sweetie 0 8 3 14 10.13 63.1 559.7 622.7 
Sweetie 14 8 2.5 11 8.49 52.5 565.7 618.2 
Sweetie 28 7.5 3 9 7.39 43.8 548.1 591.8 
Sweetie 42 7.5 3 9.5 7.67 45.5 548.1 593.6 
Sweetie 70 6.5 2 6 5.75 32.1 525.6 557.7 
Sweetie 98 5 2 4 4.66 22.5 461.1 483.6 
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Boots 1 -30 141.68 4.33 
 
Boots 2 3 294.16 15.91 
Boots 1 0 235.75 14.66 
 
Boots 2 4 310.73 12.75 
Boots 1 1 383.04 . 
 
Boots 2 5 318.94 14.87 
Boots 1 2 316.40 15.15 
 
Boots 2 6 317.84 12.64 
Boots 1 3 341.84 11.16 
 
Boots 2 7 314.74 15.10 
Boots 1 4 313.55 . 
 
Boots 2 8 299.42 12.43 
Boots 1 5 330.58 19.25 
 
Boots 2 9 290.32 10.53 
Boots 1 6 350.10 16.97 
 
Boots 2 10 287.95 11.61 
Boots 1 7 314.74 . 
 
Boots 2 12 320.33 11.18 
Boots 1 8 324.18 13.86 
 
Boots 2 14 304.45 11.19 
Boots 1 10 321.58 16.83 
 
Boots 2 16 295.61 9.36 
Boots 1 12 279.38 17.67 
 
Boots 2 19 281.13 8.54 
Boots 1 14 296.33 13.19 
 
Boots 2 22 241.12 212.42 
Boots 1 16 321.90 14.82 
 
Boots 2 23 255.45 157.48 
Boots 1 19 292.43 14.01 
 
Boots 2 24 265.69 135.75 
Boots 1 22 318.97 12.20 
 
Boots 2 25 265.34 111.98 
Boots 1 23 300.36 216.46 
 
Boots 2 27 241.13 77.04 
Boots 1 24 278.48 209.35 
 
Boots 2 30 229.18 64.57 
Boots 1 25 312.03 195.40 
 
Boots 2 35 239.62 30.20 
Boots 1 27 270.37 122.02 
 
Boots 2 40 179.81 21.09 
Boots 1 30 303.59 116.60 
 
Boots 2 50 176.35 8.72 
Boots 1 35 287.61 70.45 
 
Boots 2 60 121.16 5.01 
Boots 1 40 268.40 . 
 
Boots 2 70 125.42 3.50 
Boots 1 50 276.99 . 
 
Boots 2 80 110.32 5.55 
Boots 1 60 264.61 . 
 
Boots 2 90 108.76 3.90 
Boots 1 70 234.09 . 
 
Boots 2 100 129.76 . 
Boots 1 80 225.45 . 
 
Boots 2 120 101.34 2.78 
Boots 1 90 244.76 . 
 
Boots 2 150 109.89 2.43 
Boots 1 100 313.21 14.94 
 
Boots 2 180 103.40 2.60 
Boots 1 120 217.32 15.68 
 
Daphne 1 -30 104.14 3.71 
Boots 1 150 195.43 11.31 
 
Daphne 1 0 275.64 3.10 
Boots 1 180 161.08 5.26 
 
Daphne 1 1 299.76 26.49 
Boots 1 240 . 5.17 
 
Daphne 1 2 282.86 28.15 
Boots 2 -30 159.89 4.63 
 
Daphne 1 3 314.47 26.30 
Boots 2 0 136.29 3.90 
 
Daphne 1 4 292.44 30.51 
Boots 2 1 318.75 63.06 
 
Daphne 1 5 323.67 29.17 
Boots 2 2 315.23 13.18 
 
Daphne 1 6 317.14 30.73 
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Daphne 1 7 305.82 31.35 
 
Daphne 2 19 320.66 13.43 
Daphne 1 8 328.55 35.77 
 
Daphne 2 22 234.75 319.58 
Daphne 1 10 289.76 36.57 
 
Daphne 2 23 245.05 202.54 
Daphne 1 12 266.90 . 
 
Daphne 2 24 277.02 162.85 
Daphne 1 14 326.60 29.17 
 
Daphne 2 25 282.56 145.21 
Daphne 1 16 319.96 26.91 
 
Daphne 2 27 268.37 109.06 
Daphne 1 19 279.35 27.65 
 
Daphne 2 30 270.67 80.82 
Daphne 1 22 323.11 319.06 
 
Daphne 2 35 272.30 51.44 
Daphne 1 23 323.41 276.25 
 
Daphne 2 40 222.53 36.17 
Daphne 1 24 270.46 235.25 
 
Daphne 2 50 186.83 25.42 
Daphne 1 25 312.21 205.59 
 
Daphne 2 60 156.42 23.47 
Daphne 1 27 304.55 175.44 
 
Daphne 2 70 148.35 17.48 
Daphne 1 30 303.59 143.07 
 
Daphne 2 80 127.03 14.31 
Daphne 1 35 322.79 100.61 
 
Daphne 2 90 116.93 12.19 
Daphne 1 40 275.57 83.83 
 
Daphne 2 100 121.23 10.98 
Daphne 1 50 283.08 61.73 
 
Daphne 2 120 111.28 8.60 
Daphne 1 60 253.30 56.73 
 
Daphne 2 150 97.54 7.12 
Daphne 1 70 202.07 55.26 
 
Daphne 2 180 85.73 5.26 
Daphne 1 80 192.61 54.56 
 
Getda 1 -30 138.60 5.33 
Daphne 1 90 184.95 56.36 
 
Getda 1 0 114.40 7.82 
Daphne 1 100 211.14 52.16 
 
Getda 1 1 344.47 43.95 
Daphne 1 120 154.28 37.99 
 
Getda 1 2 339.88 49.32 
Daphne 1 150 103.36 19.97 
 
Getda 1 3 285.15 56.80 
Daphne 1 180 79.34 10.27 
 
Getda 1 4 291.63 58.64 
Daphne 1 240 78.57 2.54 
 
Getda 1 5 344.35 56.79 
Daphne 2 -30 117.99 6.75 
 
Getda 1 6 325.73 50.64 
Daphne 2 0 110.45 5.80 
 
Getda 1 7 307.23 50.23 
Daphne 2 1 311.43 18.45 
 
Getda 1 8 290.62 55.36 
Daphne 2 2 330.59 18.26 
 
Getda 1 9 . . 
Daphne 2 3 301.42 16.84 
 
Getda 1 10 289.01 53.33 
Daphne 2 4 340.42 19.77 
 
Getda 1 12 299.19 42.29 
Daphne 2 5 302.35 22.05 
 
Getda 1 14 264.01 45.03 
Daphne 2 6 299.04 . 
 
Getda 1 16 260.86 42.39 
Daphne 2 7 296.82 19.07 
 
Getda 1 19 302.16 45.08 
Daphne 2 8 308.08 17.79 
 
Getda 1 22 266.90 495.47 
Daphne 2 9 297.40 17.13 
 
Getda 1 23 312.61 290.42 
Daphne 2 10 296.06 14.90 
 
Getda 1 24 283.87 297.12 
Daphne 2 12 241.63 16.00 
 



















Daphne 2 14 306.41 13.30 
 
Getda 1 27 292.28 189.35 
Daphne 2 16 303.61 14.74 
 
Getda 1 30 257.78 160.45 
Getda 1 35 275.64 107.56 
 
Getda 2 90 144.64 34.96 
Getda 1 40 258.68 95.56 
 
Getda 2 100 . 31.25 
Getda 1 50 289.89 71.01 
 
Getda 2 120 174.23 24.20 
Getda 1 60 273.22 51.50 
 
Getda 2 150 105.65 14.75 
Getda 1 70 226.50 47.19 
 
Getda 2 180 94.60 8.67 
Getda 1 80 226.30 49.90 
 
JR 1 -30 108.86 2.10 
Getda 1 90 193.50 39.32 
 
JR 1 0 105.99 2.69 
Getda 1 100 184.48 40.32 
 
JR 1 1 297.73 14.39 
Getda 1 120 209.05 30.25 
 
JR 1 2 337.42 19.13 
Getda 1 150 308.45 25.52 
 
JR 1 3 302.18 16.34 
Getda 1 180 149.21 16.49 
 
JR 1 4 329.24 18.32 
Getda 1 240 113.62 6.84 
 
JR 1 5 303.17 25.48 
Getda 2 -30 120.66 10.00 
 
JR 1 6 302.69 27.34 
Getda 2 0 107.47 6.27 
 
JR 1 7 295.08 21.44 
Getda 2 1 266.81 56.90 
 
JR 1 8 189.98 26.11 
Getda 2 2 298.70 59.08 
 
JR 1 10 299.49 23.60 
Getda 2 3 319.24 63.57 
 
JR 1 12 304.89 22.14 
Getda 2 4 325.87 64.15 
 
JR 1 14 274.79 18.00 
Getda 2 5 267.30 60.61 
 
JR 1 16 304.23 16.38 
Getda 2 6 318.81 56.03 
 
JR 1 19 313.16 14.86 
Getda 2 7 298.33 45.81 
 
JR 1 22 309.72 13.67 
Getda 2 8 322.77 50.47 
 
JR 1 23 295.35 302.64 
Getda 2 9 330.95 50.70 
 
JR 1 24 291.86 247.29 
Getda 2 10 250.40 44.25 
 
JR 1 25 288.14 173.85 
Getda 2 12 314.18 35.23 
 
JR 1 27 259.12 155.52 
Getda 2 14 285.19 37.10 
 
JR 1 30 230.51 121.99 
Getda 2 16 277.54 33.94 
 
JR 1 35 261.32 91.19 
Getda 2 19 302.05 29.91 
 
JR 1 40 237.79 53.21 
Getda 2 22 270.00 358.34 
 
JR 1 50 324.91 34.54 
Getda 2 23 266.52 249.23 
 
JR 1 60 168.11 22.71 
Getda 2 24 262.68 142.11 
 
JR 1 70 202.77 18.25 
Getda 2 25 257.66 173.82 
 
JR 1 80 167.08 17.39 
Getda 2 27 264.22 142.79 
 
JR 1 90 146.75 14.60 
Getda 2 30 233.61 129.90 
 
JR 1 100 157.64 10.97 
Getda 2 35 271.35 69.62 
 
JR 1 120 136.10 9.93 
Getda 2 40 248.74 54.66 
 

















Getda 2 50 232.23 43.40 
 
JR 1 180 100.26 4.87 
Getda 2 60 240.93 37.20 
 
JR 1 240 287.76 4.46 
Getda 2 70 177.26 41.98 
 
JR 1 240 78.04 1.71 
Getda 2 80 174.74 18.40 
 
JR 2 -30 148.64 2.42 
JR 2 0 130.27 2.50 
 
Pistol 1 7 342.84 10.41 
JR 2 1 320.24 . 
 
Pistol 1 8 313.05 . 
JR 2 2 327.41 6.37 
 
Pistol 1 10 289.89 11.97 
JR 2 3 315.76 8.58 
 
Pistol 1 12 314.55 7.89 
JR 2 4 290.79 8.02 
 
Pistol 1 14 290.28 9.14 
JR 2 5 285.37 25.93 
 
Pistol 1 16 264.40 9.08 
JR 2 6 311.66 9.88 
 
Pistol 1 19 299.17 8.19 
JR 2 7 311.00 9.23 
 
Pistol 1 22 287.48 8.63 
JR 2 8 315.39 14.32 
 
Pistol 1 23 281.68 395.19 
JR 2 9 269.32 7.45 
 
Pistol 1 24 242.53 252.88 
JR 2 10 272.96 7.36 
 
Pistol 1 25 268.86 192.34 
JR 2 12 336.17 5.89 
 
Pistol 1 27 317.90 163.09 
JR 2 14 289.88 6.07 
 
Pistol 1 30 237.00 119.10 
JR 2 16 291.67 6.45 
 
Pistol 1 35 224.42 353.29 
JR 2 19 282.97 6.71 
 
Pistol 1 40 183.77 59.27 
JR 2 22 289.91 321.57 
 
Pistol 1 50 176.49 29.60 
JR 2 23 322.04 198.99 
 
Pistol 1 60 155.34 21.75 
JR 2 24 262.25 176.21 
 
Pistol 1 70 127.26 11.86 
JR 2 25 288.42 158.79 
 
Pistol 1 80 113.37 7.75 
JR 2 27 252.68 217.74 
 
Pistol 1 90 125.19 7.90 
JR 2 30 250.13 120.06 
 
Pistol 1 100 126.05 5.29 
JR 2 35 220.81 37.16 
 
Pistol 1 120 85.34 5.33 
JR 2 40 214.27 20.77 
 
Pistol 1 150 65.95 3.71 
JR 2 50 184.37 50.87 
 
Pistol 1 180 98.39 1.84 
JR 2 60 144.35 9.03 
 
Pistol 1 240 96.58 2.98 
JR 2 70 119.47 119.93 
 
Pistol 2 -30 143.88 4.21 
JR 2 80 114.55 13.51 
 
Pistol 2 0 124.62 4.40 
JR 2 90 103.97 3.95 
 
Pistol 2 1 337.21 13.71 
JR 2 100 117.25 7.12 
 
Pistol 2 2 336.26 12.13 
JR 2 120 97.26 3.08 
 
Pistol 2 3 332.70 . 
JR 2 150 87.47 2.31 
 
Pistol 2 4 329.72 11.67 
JR 2 180 86.44 2.96 
 
Pistol 2 5 330.89 12.30 
Pistol 1 -30 111.13 4.13 
 
Pistol 2 6 334.39 9.36 
Pistol 1 0 299.54 2.27 
 

















Pistol 1 1 331.75 10.63 
 
Pistol 2 8 291.72 11.81 
Pistol 1 2 286.25 10.49 
 
Pistol 2 9 341.71 11.48 
Pistol 1 3 330.15 8.69 
 
Pistol 2 10 318.60 11.85 
Pistol 1 4 296.46 9.64 
 
Pistol 2 12 278.93 . 
Pistol 1 5 285.39 9.58 
 
Pistol 2 14 278.68 12.85 
Pistol 1 6 292.23 11.08 
 
Pistol 2 16 268.34 10.90 
Pistol 2 19 286.03 9.00 
 
Romeo 1 50 282.39 55.03 
Pistol 2 22 267.53 361.97 
 
Romeo 1 60 235.25 53.85 
Pistol 2 23 297.68 107.58 
 
Romeo 1 70 202.24 51.10 
Pistol 2 24 276.09 131.03 
 
Romeo 1 80 192.67 44.16 
Pistol 2 25 275.05 108.16 
 
Romeo 1 90 186.06 37.31 
Pistol 2 30 225.25 65.84 
 
Romeo 1 100 157.54 28.18 
Pistol 2 35 168.86 35.75 
 
Romeo 1 120 211.14 31.38 
Pistol 2 40 140.53 20.30 
 
Romeo 1 150 337.94 14.72 
Pistol 2 50 86.59 9.27 
 
Romeo 1 180 255.43 9.05 
Pistol 2 60 69.00 6.77 
 
Romeo 1 240 105.64 2.51 
Pistol 2 70 68.62 6.57 
 
Romeo 2 -30 140.70 5.13 
Pistol 2 80 57.62 4.32 
 
Romeo 2 0 129.23 4.53 
Pistol 2 90 52.74 3.66 
 
Romeo 2 1 281.98 14.31 
Pistol 2 100 50.60 2.63 
 
Romeo 2 2 322.27 15.36 
Pistol 2 120 68.77 1.82 
 
Romeo 2 3 274.44 16.36 
Pistol 2 150 87.14 1.60 
 
Romeo 2 4 246.25 14.74 
Pistol 2 180 102.43 2.04 
 
Romeo 2 5 302.45 15.45 
Romeo 1 -30 114.31 5.19 
 
Romeo 2 7 287.79 17.11 
Romeo 1 0 117.09 3.70 
 
Romeo 2 8 336.73 15.84 
Romeo 1 1 348.64 17.50 
 
Romeo 2 9 314.70 18.54 
Romeo 1 2 332.08 25.20 
 
Romeo 2 10 307.11 19.37 
Romeo 1 3 346.00 23.85 
 
Romeo 2 12 316.01 18.87 
Romeo 1 4 367.21 27.98 
 
Romeo 2 14 302.65 15.43 
Romeo 1 5 311.30 29.71 
 
Romeo 2 16 314.29 17.40 
Romeo 1 6 327.86 27.57 
 
Romeo 2 19 320.92 18.92 
Romeo 1 7 326.15 24.94 
 
Romeo 2 22 310.95 . 
Romeo 1 8 302.74 34.96 
 
Romeo 2 23 243.62 186.49 
Romeo 1 10 292.95 25.51 
 
Romeo 2 24 357.99 176.86 
Romeo 1 12 113.74 23.63 
 
Romeo 2 25 308.35 147.98 
Romeo 1 14 320.17 20.59 
 
Romeo 2 27 323.50 124.21 
Romeo 1 16 295.35 26.92 
 
Romeo 2 30 245.06 93.96 
Romeo 1 19 117.29 21.39 
 

















Romeo 1 22 292.27 522.57 
 
Romeo 2 40 238.32 49.50 
Romeo 1 23 287.28 324.23 
 
Romeo 2 50 215.14 36.65 
Romeo 1 24 321.94 257.02 
 
Romeo 2 60 176.18 28.95 
Romeo 1 25 288.66 227.44 
 
Romeo 2 70 166.94 24.43 
Romeo 1 27 257.60 160.16 
 
Romeo 2 80 169.77 19.03 
Romeo 1 30 266.31 125.96 
 
Romeo 2 90 144.03 15.19 
Romeo 1 35 247.16 88.73 
 
Romeo 2 100 130.09 10.68 
Romeo 1 40 241.42 72.41 
 
Romeo 2 120 111.29 7.76 
Romeo 2 150 132.52 5.81 
 
Susie 2 3 330.13 47.42 
Romeo 2 180 106.01 6.97 
 
Susie 2 4 290.34 49.33 
Susie 1 -30 151.02 4.70 
 
Susie 2 5 256.96 54.56 
Susie 1 0 134.90 3.37 
 
Susie 2 6 291.88 60.87 
Susie 1 1 345.60 34.23 
 
Susie 2 7 293.56 60.34 
Susie 1 2 327.47 38.59 
 
Susie 2 8 . . 
Susie 1 3 378.50 41.22 
 
Susie 2 9 282.61 49.29 
Susie 1 4 329.47 43.46 
 
Susie 2 10 266.52 66.02 
Susie 1 5 289.63 43.47 
 
Susie 2 12 285.17 515.54 
Susie 1 6 296.18 44.92 
 
Susie 2 14 240.66 65.98 
Susie 1 7 286.78 39.93 
 
Susie 2 16 263.02 63.36 
Susie 1 8 303.82 44.90 
 
Susie 2 19 224.48 73.58 
Susie 1 9 . . 
 
Susie 2 22 . . 
Susie 1 10 311.66 40.50 
 
Susie 2 23 198.83 246.49 
Susie 1 12 306.46 40.63 
 
Susie 2 24 200.73 245.68 
Susie 1 14 278.22 35.57 
 
Susie 2 25 172.00 204.87 
Susie 1 16 162.34 31.48 
 
Susie 2 27 152.99 193.09 
Susie 1 19 269.96 30.29 
 
Susie 2 30 110.91 151.79 
Susie 1 22 255.74 544.49 
 
Susie 2 35 107.01 94.55 
Susie 1 23 . . 
 
Susie 2 40 89.59 56.07 
Susie 1 24 . . 
 
Susie 2 50 . 15.17 
Susie 1 25 300.71 258.13 
 
Susie 2 60 . 10.21 
Susie 1 27 277.39 201.34 
 
Susie 2 70 . 6.78 
Susie 1 30 268.37 . 
 
Susie 2 80 . 3.33 
Susie 1 35 247.17 119.91 
 
Susie 2 90 . 3.08 
Susie 1 40 . . 
 
Susie 2 100 . 2.35 
Susie 1 50 202.73 69.90 
 
Susie 2 120 78.74 1.98 
Susie 1 60 201.88 43.40 
 
Susie 2 150 92.35 3.17 
Susie 1 70 157.00 46.50 
 
Susie 2 180 112.73 2.24 
Susie 1 80 145.49 43.93 
 

















Susie 1 90 154.40 32.30 
 
Sweetie 1 0 136.04 7.67 
Susie 1 100 141.79 26.92 
 
Sweetie 1 1 334.92 58.87 
Susie 1 120 114.86 21.93 
 
Sweetie 1 2 332.40 62.43 
Susie 1 150 . . 
 
Sweetie 1 3 305.52 60.07 
Susie 1 180 . 12.74 
 
Sweetie 1 4 311.66 60.22 
Susie 1 240 74.85 2.49 
 
Sweetie 1 5 302.00 62.74 
Susie 2 -30 113.92 5.47 
 
Sweetie 1 6 344.73 57.02 
Susie 2 0 106.18 4.68 
 
Sweetie 1 7 310.00 66.02 
Susie 2 1 307.40 43.35 
 
Sweetie 1 8 337.66 50.02 
Susie 2 2 311.16 45.94 
 
Sweetie 1 9 . . 
Sweetie 1 10 309.75 46.88 
 
Sweetie 2 4 347.50 23.53 
Sweetie 1 12 298.57 44.56 
 
Sweetie 2 5 313.90 . 
Sweetie 1 14 287.51 37.31 
 
Sweetie 2 6 336.69 19.10 
Sweetie 1 16 321.13 45.16 
 
Sweetie 2 7 326.22 20.44 
Sweetie 1 19 286.93 . 
 
Sweetie 2 8 268.01 21.20 
Sweetie 1 22 290.88 527.60 
 
Sweetie 2 9 335.11 22.79 
Sweetie 1 23 252.36 400.93 
 
Sweetie 2 10 297.31 20.20 
Sweetie 1 24 298.98 313.89 
 
Sweetie 2 12 311.83 16.68 
Sweetie 1 25 270.15 255.29 
 
Sweetie 2 14 287.89 17.06 
Sweetie 1 27 293.41 242.63 
 
Sweetie 2 16 293.32 . 
Sweetie 1 30 250.15 193.69 
 
Sweetie 2 19 321.14 18.09 
Sweetie 1 35 302.59 140.69 
 
Sweetie 2 22 320.03 206.32 
Sweetie 1 40 277.03 115.78 
 
Sweetie 2 23 247.99 194.44 
Sweetie 1 50 242.02 99.41 
 
Sweetie 2 24 233.56 99.58 
Sweetie 1 60 252.28 65.98 
 
Sweetie 2 25 259.53 143.98 
Sweetie 1 70 247.55 68.87 
 
Sweetie 2 27 284.15 107.95 
Sweetie 1 80 261.34 69.03 
 
Sweetie 2 30 282.03 89.04 
Sweetie 1 90 233.25 53.76 
 
Sweetie 2 24 233.56 99.58 
Sweetie 1 100 176.97 53.63 
 
Sweetie 2 25 259.53 143.98 
Sweetie 1 120 230.25 62.01 
 
Sweetie 2 27 284.15 107.95 
Sweetie 1 150 144.10 33.95 
 
Sweetie 2 30 282.03 89.04 
Sweetie 1 180 134.94 20.29 
 
Sweetie 2 35 231.00 53.53 
Sweetie 1 240 114.65 65.82 
 
Sweetie 2 40 227.79 42.53 
Sweetie 2 -30 159.92 5.26 
 
Sweetie 2 50 199.06 26.83 
Sweetie 2 0 133.16 6.05 
 
Sweetie 2 60 173.27 20.51 
Sweetie 2 1 360.98 27.47 
 
Sweetie 2 70 160.61 3.07 
Sweetie 2 2 332.12 21.87 
 
Sweetie 2 80 146.96 9.83 
Sweetie 2 3 266.49 224.58 
 










Sweetie 2 100 144.65 13.23 
Sweetie 2 120 116.26 12.02 
Sweetie 2 150 117.14 6.55 
Sweetie 2 180 119.19 3.14 
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Boots 0 3.30 0 0.790 0.021 
Boots 14 0.00 0 0.720 0.006 
Boots 28 5.27 0 0.782 0.005 
Boots 42 5.80 0 0.730 0.008 
Boots 70 
 
-1.5 0.796 0.014 
Boots 98 12.50 -3 0.701 0.010 
Daphne 0 -0.42 0 . . 
Daphne 14 0.00 0 1.291 0.029 
Daphne 28 0.21 0 0.693 0.007 
Daphne 42 1.69 0 0.755 0.009 
Daphne 70 
 
-1 0.630 0.014 
Daphne 98 4.44 -3 0.676 0.008 
Getda 0 -0.87 0 0.884 0.009 
Getda 14 0.00 0 0.823 0.029 
Getda 28 1.67 -0.5 0.764 0.031 
Getda 42 2.78 -0.5 0.700 0.007 
Getda 70 
 
-2.5 0.641 0.009 
Getda 98 6.83 -3 0.586 0.011 
JR 0 -3.16 1 0.672 0.032 
JR 14 0.00 0 0.813 0.017 
JR 28 2.98 -0.5 0.626 0.005 
JR 42 4.04 -1 0.575 0.015 
JR 70 7.37 -2 0.714 0.006 
Pistol 0 -1.78 -0.5 0.738 0.007 
Pistol 14 0.00 0 0.816 0.012 
Pistol 28 -1.13 0 0.762 0.020 
Pistol 42 -0.47 0 0.805 0.005 
Pistol 70 
 
-1 0.606 0.011 
Pistol 98 2.91 -2.5 0.651 0.015 
Romeo 0 0.85 0 0.976 0.017 
Romeo 14 0.00 0 0.732 0.013 
Romeo 28 3.20 -0.5 0.981 0.017 
Romeo 42 3.66 -0.5 0.829 0.010 
Romeo 70 
 
-2.5 0.852 0.011 

















Susie 0 -0.76 0 . . 
Susie 14 0.00 0 0.884 0.009 
Susie 28 0.08 -0.5 0.677 0.008 
Susie 42 1.43 -0.5 0.537 0.009 
Susie 70 
 
-1 . . 
Susie 98 5.63 -2.5 0.640 0.017 
Sweetie 0 -0.74 0 1.171 0.033 
Sweetie 14 0.00 0 0.762 0.007 
Sweetie 28 4.26 -0.5 0.666 0.007 
Sweetie 42 3.97 -0.5 0.657 0.012 
Sweetie 70 
 
-1.5 0.751 0.013 
Sweetie 98 21.76 -3 0.703 0.010 
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Boots 0 IFM 67.80 443.94 183.49 
Boots 14 IFM 57.13 280.52 245.19 
Boots 28 IFM 77.62 59.29 145.69 
Boots 42 IFM 56.90 58.21 139.71 
Boots 70 IFM 56.86 62.05 68.25 
Boots 98 IFM 102.00 55.65 84.59 
Boots 0 SSM 19.40 60.47 34.47 
Boots 14 SSM 16.63 136.14 71.88 
Boots 28 SSM 21.38 69.98 74.18 
Boots 42 SSM 28.85 23.62 94.46 
Boots 70 SSM 43.31 15.19 44.56 
Boots 98 SSM 37.05 15.16 87.93 
Daphne 0 IFM 37.00 226.44 72.67 
Daphne 14 IFM 31.98 73.28 113.06 
Daphne 28 IFM 74.34 89.66 117.84 
Daphne 42 IFM 48.52 49.64 115.15 
Daphne 70 IFM 31.95 12.07 94.95 
Daphne 98 IFM 42.70 25.41 58.45 
Daphne 0 SSM 68.57 67.82 52.38 
Daphne 14 SSM . . . 
Daphne 28 SSM 46.06 99.78 47.01 
Daphne 42 SSM 45.37 49.51 77.24 
Daphne 70 SSM 49.92 9.90 61.41 
Daphne 98 SSM 20.24 11.05 50.37 
Getda 0 IFM 62.34 209.73 151.92 
Getda 14 IFM 72.31 114.28 102.86 
Getda 28 IFM 102.55 95.92 206.22 
Getda 42 IFM 18.52 20.21 53.91 
Getda 70 IFM 22.05 31.59 108.30 
Getda 98 IFM 36.95 36.29 58.06 
Getda 0 SSM 83.09 149.61 52.59 
Getda 14 SSM 34.57 78.34 41.78 
Getda 28 SSM 49.56 117.18 72.11 
Getda 42 SSM 58.66 10.67 64.01 
Getda 70 SSM 39.34 18.94 84.85 










JR 0 IFM 54.15 166.18 163.97 
JR 14 IFM 88.62 99.25 61.08 
JR 28 IFM 49.95 81.76 110.37 
JR 42 IFM 44.45 62.36 62.36 
JR 70 IFM 49.82 58.25 65.24 
JR 0 SSM 47.52 77.78 68.15 
JR 14 SSM 32.85 132.35 92.64 
JR 28 SSM 55.48 45.41 60.08 
JR 42 SSM 50.58 34.50 115.91 
JR 70 SSM 55.62 32.13 74.97 
Pistol 0 IFM 31.90 174.07 85.87 
Pistol 14 IFM 167.61 108.87 83.61 
Pistol 28 IFM 83.45 150.25 234.94 
Pistol 42 IFM 54.19 40.32 129.02 
Pistol 70 IFM 34.57 21.22 101.85 
Pistol 98 IFM 50.58 68.99 137.98 
Pistol 0 SSM 45.12 45.22 22.31 
Pistol 14 SSM 27.09 147.81 65.04 
Pistol 28 SSM 39.20 133.66 72.71 
Pistol 42 SSM 17.85 8.35 18.37 
Pistol 70 SSM 14.17 11.60 57.98 
Pistol 98 SSM 21.72 16.16 53.01 
Romeo 0 IFM 41.07 82.16 137.43 
Romeo 14 IFM 78.85 109.71 144.55 
Romeo 28 IFM . . 159.95 
Romeo 42 IFM 37.15 23.39 76.71 
Romeo 70 IFM . 20.64 80.49 
Romeo 98 IFM 33.08 23.20 4.64 
Romeo 0 SSM 37.80 45.21 39.02 
Romeo 14 SSM 39.74 140.12 104.09 
Romeo 28 SSM 44.51 . 60.93 
Romeo 42 SSM 19.95 14.51 56.59 
Romeo 70 SSM 44.66 33.74 94.48 
Romeo 98 SSM 38.76 23.79 65.02 
Susie 0 IFM 18.53 64.46 62.18 
Susie 14 IFM 43.58 103.76 103.76 
Susie 28 IFM . . 155.22 









Susie 70 IFM 34.64 37.81 109.64 
Susie 98 IFM 28.54 26.69 26.69 
Susie 0 SSM 28.05 52.48 85.28 
Susie 14 SSM 55.61 75.86 64.73 
Susie 28 SSM 40.96 52.15 137.07 
Susie 42 SSM 42.08 9.84 58.06 
Susie 70 SSM 28.48 19.98 53.28 
Susie 98 SSM 23.18 12.65 40.48 
Sweetie 0 IFM 26.15 61.82 70.38 
Sweetie 14 IFM 65.68 107.51 225.78 
Sweetie 28 IFM 42.84 105.18 154.26 
Sweetie 42 IFM 73.28 66.64 175.93 
Sweetie 70 IFM 64.51 44.00 144.31 
Sweetie 98 IFM 18.48 45.38 . 
Sweetie 0 SSM 26.54 100.48 67.35 
Sweetie 14 SSM 37.74 103.90 69.64 
Sweetie 28 SSM 19.70 89.32 60.54 
Sweetie 42 SSM 28.90 47.31 87.52 
Sweetie 70 SSM 32.68 35.66 87.97 
Sweetie 98 SSM 9.43 15.44 30.88 
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Boots 0 IFM 1.406 113.12 0.1527 
Boots 14 IFM 3.948 63.68 0.3232 
Boots 28 IFM 2.414 76.84 0.1750 
Boots 42 IFM . 47.99 0.1868 
Boots 70 IFM 4.421 19.84 0.1073 
Boots 98 IFM 2.115 51.23 0.1578 
Boots 0 SSM 2.442 306.17 . 
Boots 14 SSM 2.328 282.26 0.4316 
Boots 28 SSM 1.994 325.64 . 
Boots 42 SSM 1.683 154.15 0.3476 
Boots 70 SSM 1.684 220.59 0.4313 
Boots 98 SSM 2.881 294.64 0.3793 
Daphne 0 IFM 2.501 238.78 0.7276 
Daphne 14 IFM 1.492 97.84 0.7900 
Daphne 28 IFM 1.825 110.57 0.3792 
Daphne 42 IFM 1.886 33.86 0.2320 
Daphne 70 IFM 0.764 265.58 0.4550 
Daphne 98 IFM 1.207 94.69 0.3296 
Daphne 0 SSM 1.111 273.64 0.6772 
Daphne 14 SSM . . . 
Daphne 28 SSM 1.264 383.69 0.4165 
Daphne 42 SSM 0.941 141.09 0.4906 
Daphne 70 SSM 2.117 408.31 0.9560 
Daphne 98 SSM 1.259 378.65 . 
Getda 0 IFM 1.616 151.49 0.8532 
Getda 14 IFM 2.714 186.71 0.7077 
Getda 28 IFM 2.278 87.91 0.6325 
Getda 42 IFM 0.960 129.68 0.2622 
Getda 70 IFM 1.286 172.08 0.2638 
Getda 98 IFM 1.724 143.35 . 
Getda 0 SSM 1.938 529.52 0.5126 
Getda 14 SSM 1.240 503.41 0.3804 
Getda 28 SSM 2.997 225.83 0.8267 
Getda 42 SSM 1.520 373.12 0.5553 
Getda 70 SSM 2.159 235.05 0.5131 













JR 0 IFM 2.105 49.45 . 
JR 14 IFM 2.176 35.91 0.2424 
JR 28 IFM 0.971 30.30 0.1102 
JR 42 IFM 4.937 21.69 0.1907 
JR 70 IFM 1.107 35.89 0.0683 
JR 0 SSM 1.407 150.90 0.6942 
JR 14 SSM 2.357 187.61 0.5711 
JR 28 SSM 3.982 185.10 0.3491 
JR 42 SSM 1.311 99.81 0.2718 
JR 70 SSM 2.544 128.76 0.2675 
Pistol 0 IFM 1.654 36.95 0.0949 
Pistol 14 IFM 4.551 64.51 0.0967 
Pistol 28 IFM 2.595 52.89 0.1442 
Pistol 42 IFM 1.532 60.13 0.3293 
Pistol 70 IFM 0.672 46.33 0.0459 
Pistol 98 IFM 3.933 37.44 0.0821 
Pistol 0 SSM 2.291 243.48 0.8462 
Pistol 14 SSM 2.808 264.03 0.4042 
Pistol 28 SSM 4.571 173.59 0.2529 
Pistol 42 SSM 1.454 230.30 0.5857 
Pistol 70 SSM 1.377 168.69 0.3518 
Pistol 98 SSM 0.921 263.28 0.2470 
Romeo 0 IFM 2.129 66.75 . 
Romeo 14 IFM 8.583 93.45 0.5432 
Romeo 28 IFM 2.235 85.66 0.3866 
Romeo 42 IFM 0.889 89.45 0.4396 
Romeo 70 IFM 0.980 137.63 0.1774 
Romeo 98 IFM 2.572 85.41 0.3240 
Romeo 0 SSM 2.939 267.18 . 
Romeo 14 SSM 4.754 229.50 0.1669 
Romeo 28 SSM 2.831 183.31 0.4122 
Romeo 42 SSM 3.446 221.28 0.4324 
Romeo 70 SSM 3.205 219.82 0.3687 
Romeo 98 SSM 1.130 292.59 0.3497 
Susie 0 IFM 1.081 89.38 0.3483 
Susie 14 IFM 1.232 61.69 0.2953 
Susie 28 IFM 2.633 40.14 0.3365 











Susie 70 IFM 1.796 61.81 0.3624 
Susie 98 IFM 1.268 86.16 0.2618 
Susie 0 SSM 1.870 195.80 0.5381 
Susie 14 SSM 1.441 334.50 0.4622 
Susie 28 SSM 2.123 122.79 0.3825 
Susie 42 SSM 1.870 373.73 0.3802 
Susie 70 SSM 1.582 297.03 . 
Susie 98 SSM 1.803 300.94 0.4682 
Sweetie 0 IFM 3.162 31.57 0.5239 
Sweetie 14 IFM 3.830 50.87 0.2193 
Sweetie 28 IFM 2.498 63.08 0.4065 
Sweetie 42 IFM 1.266 42.02 0.1979 
Sweetie 70 IFM 1.672 53.64 0.1215 
Sweetie 98 IFM 1.437 40.63 0.0817 
Sweetie 0 SSM 1.548 254.97 0.7668 
Sweetie 14 SSM 1.067 298.52 0.4283 
Sweetie 28 SSM 0.943 269.80 0.2072 
Sweetie 42 SSM 1.685 160.82 0.2615 
Sweetie 70 SSM 4.517 162.81 . 
Sweetie 98 SSM 2.054 136.21 0.4772 
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